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ABSTRACT 
 
The incidence of cardiovascular diseases, including hypertension, is on the increase 
worldwide. Medicinal plants played an important role in the treatment of hypertension for 
centuries. Very few scientific studies have, however, been done to validate the use of 
these phytotherapies. O africana is one of the many phytotherapies that has been used 
indigenously for years to treat hypertension. 
 
The objectives of this study were: 
? To determine the most effective dose of O africana aqueous extract which will 
reduce blood pressure 
? To determine whether chronic administration of O africana can be used 
i) to prevent hypertension 
ii) to treat hypertension 
? To determine whether O africana exert its effects by modulation of the renin-
angiotensin system. 
 
To realize these objectives, 42 normotensive Dahl Salt-Sensitive (DSS) rats (n=6 in each 
group) and 12 hypertensive DSS rats (n=6 in each group) were used for single injection 
experiments to determine the acute blood pressure lowering effect of the aqueous extract 
of O africana leaves. Another 48 DSS rats were divided into 6 groups (n=8 in each 
group) to compare the chronic antihypertensive effect of aqueous extract of O africana 
leaves with that of the classic angiotensin converting enzyme inhibitor (captopril) and 
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calcium channel blocker (nifedipine). At the end of the experiments, blood samples were 
collected and assayed by ELISA to determine the plasma angiotensin II levels. 
 
The blood pressure in hypertensive rats, induced by the administration of 2% NaCl in the 
drinking water for 2 weeks, was 204.83 ± 4.13/ 145.00 ± 2.58 mmHg. The results show 
that graded doses of aqueous extract of O africana leaves produced a significant acute 
lowering effect on blood pressure in normotensive rats, except at the lowest dose of 10 
mg/kg (p<0.05 to p<0.001). The most effective dose was 1000 mg/kg. In hypertensive 
rats the dose of 1000 mg/kg was more effective than in normotensive rats (p <0.001). 
 
Both aqueous extract of O africana leaves (1000 mg/kg) and captopril (50 mg/kg) 
prevented DSS rats from becoming hypertensive when administered 2% NaCl for 2 
weeks. There was no significant difference between these groups. Nifedipine (10 mg/kg) 
gave a similar effect. An ELISA showed that plasma AII levels were significantly lower 
(p<0.001) in the extract group (13.57 ± 0.62 pg/ml) and captopril group (32.06 ± 2.97 
pg/ml) in comparison with the high salt group (270.83 ± 9.76 pg/ml). Nifedipine, on the 
other hand, did not lower plasma AII levels (p>0.05). 
 
After inducing hypertension by 2% NaCl in the drinking water for 1 week, O africana 
(1000 mg/kg) lowered blood pressure to normal levels within 1 week. 
 
Thus, the results showed that graded doses of aqueous extract of O africana leaves have 
significant blood pressure lowering effects in both normotensive and hypertensive rats. 
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The most effective concentration was found to be 1000 mg/kg. Aqueous extract of O 
africana leaves produced better antihypertensive effects in hypertensive rats than in 
normotensive rats and  prevented salt-sensitive rats from becoming hypertensive. The 
mechanism by which O africana exert its antihypertensive effects is by preventing AII 
formation, probably by acting as an ACE inhibitor. 
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CHAPTER 1 
INTRODUCTION 
 
Hypertension remains a major health problem in most countries because of its impact on 
the population mortality and morbidity. Worldwide, according to World Health 
Organization (WHO) report, hypertension is estimated to cause 7.1 million premature 
deaths and 4.5% of the disease burden annually (WHO, 2002-a). 
 
The treatment of hypertension mainly relies on synthetic medicines. Several drug classes 
have been used in the treatment of hypertension in the past forty years. These include 
diuretics, beta blockers (β-blockers), calcium channel blockers (CCB’s) and more 
recently, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers. The data from more than 20 randomized controlled trials demonstrate 
reductions in both mortality and morbidity with these drug classes (Neal B, et al, 2000; 
WHO, 2003). 
 
The use of these synthetic medicines however, has some negative effects. Most drugs 
used to treat hypertension have been evaluated for a number of specific patient 
populations; these include ACE inhibitors, β-blockers, CCB’s and diuretics in patients 
with concomitant diabetes, nephropathy, coronary and cerebrovascular disease, heart 
failure, and left ventricular hypertrophy (WHO, 2003). Side effects of these synthetic 
medicines have also been reported. For example, dry cough is a common side-effect of 
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ACE inhibitors and is a major limiting factor of their use (Ahmad M, et al, 2005). 
Secondly, despite the availability of useful non-drug therapy and potent medications, 
treatment is too often ineffective, mainly as a consequence of the patient’s lack of 
compliance with therapeutic regimens (WHO, 2003). Moreover, because of limited 
resources, synthetic drug treatment may not be affordable to the majority of hypertensive 
patients. 
 
There are many herbal medicines traditionally used to treat hypertension in many 
countries. These herbal medicines are much easier and cheaper to obtain than the 
synthetic medicines, and fewer side effects are reported. 
 
O europaea is one of these medicinal plants, and has shown significant antihypertensive 
effect (Khayyyal MT, et al, 2002). O africana is a subspecies of O europaea, which is 
indigenous to Africa. In previous scientific studies, the extract of roots and stems of O 
africana has been shown to possess antihypertensive activity (Osim E, et al, 1999), also 
the ethanol leaves extract was shown to be hypotensive (Somova LI, et al, 2003). 
 
Very few studies have been done to determine the antihypertensive effects of the aqueous 
extract of O africana leaves. Considering that O africana leaves are used most often by 
drinking as a tea, more attention should be given to the aqueous extract of O africana 
leaves. Furthermore, no scientific articles are published on comparison of O africana 
extract with other classic antihypertensive drugs. The mechanism by which O africana 
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extract performs its hypotensive effect is also not clear (Rauwald HW, et al, 1994; 
Khayyyal MT, et al, 2002). 
 
The objectives of this study were: 
? To determine the most effective dose of O africana aqueous extract which will 
reduce blood pressure 
? To determine whether chronic administration of O africana can be used  
i) to prevent hypertension 
ii) to treat hypertension 
? To determine whether O africana exert its effects by modulation of the 
renin-angiotensin system. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Hypertension  
2.1.1 A global perspective  
Hypertension is becoming one of the most prevalent diseases all over the world. 
Elevation of both systolic and diastolic blood pressures is associated with increased risk 
of cardiovascular diseases, like left ventricle hypertrophy (LVH), myocardial infarction, 
heart failure, strokes, and so on. Blood pressure depends on the amount of blood that the 
heart pumps out with each contraction, as well as the ease with which this blood flows 
through even the smallest blood vessels. The narrower the blood vessel, the more difficult 
it is for the blood to flow through and the higher the blood pressure gets. A definition of 
hypertension should therefore include both diastolic and systolic blood pressure criteria. 
The World Health Organization (WHO) defines hypertension as the situation when 
arterial pressure is greater than 140/90 mmHg for an extended period (Al-Nozha, et al, 
1997). 
 
The treatment of hypertension has been shown to prevent cardiovascular diseases and to 
extend and improve life, yet hypertension remains inadequately managed. Worldwide, 
the prevalence of hypertension is more than 600 million according to WHO (2002-b). In 
America, it affects around 50 million Americans (one in four American adults). Of those 
with hypertension, about 68% are aware of their condition, but only 27% have it under 
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control (Aram VC, et al, 2003). Population surveys in a number of African countries also 
indicate that hypertension rates are on the rise. In South Africa, it affects 16% of the 
population according to the WHO/ISH Guidelines (WHO/ISH Guidelines, 2003). In 
Zimbabwe it has reached 30% among adults (Osim ZZ, et al, 1999). 
 
2.1.2 Types of Hypertension  
Primary hypertension and secondary hypertension are the two major types of systemic 
hypertension. Primary hypertension, which has no underlying cause, accounts for 95% of 
all cases of hypertension. This type of hypertension cannot be cured but can be kept 
under control by regular, ongoing treatment. Secondary hypertension, which is much less 
common, is caused by some other underlying condition (Fox SI, 2002). This kind of 
hypertension is often cured once the original medical problem is cured.  
 
Based on the severity of the disease hypertensive individuals can be classified as 
indicated in Table 2-1 as below: 
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Table 2-1. Classification of Hypertensive Individuals 
Stage SBP (mmHg) DBP (mmHg) Presence of TOD or 
other risk factors 
Optimal ＜120 ＜80 Yes/No 
Normal  120-134 80-85 Yes/No 
Stage 1u 135-149 86-95 No 
Stage 1c 135-149 86-95 Yes 
Stage 2u 150-180 96-110 No 
Stage 2c 150-180 96-110 Yes 
Stage 3u ＞180 ＞110 No 
Stage 3c ＞180 ＞110 Yes 
TOD: Target-organ damage; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure. 
Subscript u indicates uncomplicated (free of TOD or other cardiovascular risk factors); subscript c, 
complicated (TOD or other cardiovascular risk factors are present) 
Reproduced from: Black HR and Yi JY, 1996. 
 
Apart from systemic hypertension described above the following also occurs: 
 
Hypertension during pregnancy: Gestational hypertension is the early stages of high 
blood pressure during pregnancy. Preeclampsia is the severe high blood pressure during 
pregnancy. Eclampsia is very severe pregnancy hypertension leading to seizures (Baha M 
and Sibai MD, 2003).  
 
Pulmonary hypertension is hypertension occurring in the pulmonary arteries.  
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2.1.3 Appraisal of risks 
Hypertension is a significant risk factor for the development of other types of 
cardiovascular diseases (CVD’s), including congestive heart failure and cerebrovascular 
accidents. Of the 16.6 million deaths from cardiovascular disease every year, 7.2 million 
are due to ischaemic heart disease, 5.5 million to cerebrovascular disease, and an 
additional 3.9 million to hypertensive and other heart conditions (WHO/ISH Guidelines, 
2003). 
 
Decisions about the management of patients with hypertension should not be based on 
the level of blood pressure alone, but also on the presence of other risk factors, 
concomitant diseases such as diabetes, target-organ damage and cardiovascular or renal 
disease, as well as other aspects of the patient's personal, medical and social situation. 
According to the 1999 WHO/ISH Guidelines (WHO/ISH Guidelines, 1999), four 
categories of absolute cardiovascular disease risk are defined (low, medium, high and 
very high risk). Each category represents a range of absolute disease risks. Among 
individuals in the category, the risk of a major cardiovascular event in the next 10 years is 
typically: less than 15% (low risk); 15-20% (medium risk); 20-30% (high risk); and 
greater than 30% (very high risk) (See Table 2-2 and Table 2-3). 
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Table 2-2 Factors influencing prognosis of patients with hypertension  
 
Risk factors for cardiovascular disease Target-organ damage (TOD) Associated clinical conditions (ACC) 
Levels of systolic and diastolic blood 
pressure (grades 1-3) 
Males > 55 years 
Females > 65 years 
Smoking 
Total cholesterol >6.1 mmol/l (240 
mg/dl) or LDL-cholesterol >4.0 mmol/l 
(160 mg/dl)  
HDL-cholesterol M <1.0, F <1.2 
mmol/l (<40, 45 mg/dl) 
History of cardiovascular disease in 
first-degree relatives before age 50 
Obesity, physical inactivity 
Left ventricular hypertrophy 
(electrocardiogram or 
echocardiogram) 
Microalbuminuria (20-30 mg/day) 
Radiological or ultrasound 
evidence of extensive 
atherosclerotic plaque (aorta, 
carotid, coronary, iliac and femoral 
arteries) 
Hypertensive retinopathy grade III 
or IV 
Diabetes 
Cerebrovascular disease 
Ischemic stroke 
Cerebral hemorrhage 
Transient ischemic attack 
Heart disease 
Myocardial infarction 
Angina 
Coronary revascularization 
Congestive heart failure 
Renal disease 
Plasma creatinine concentration: 
Females <1.4, males >1.5 mg/dl (120, 
133 µmol/l) 
Albuminuria >300mg/day 
Peripheral vascular disease 
Lower levels of total and low-density lipoprotein (LDL)-cholesterol are known to delineate increased risk 
but thet were not used in the stratification table. HDL, high-density lipoprotein.  Reproduced from: 
WHO/ISH WHO/ISH Guidelines, 2003.  
 
Table 2-3 Stratification of risk to quantify prognosis 
 
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; TOD: Target-organ damage; ACC: 
Associated clinical conditions.  
Reproduced from: WHO/ISH WHO/ISH Guidelines, 2003.  
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2.1.4 Hypertension in South Africa. 
The South African Demographic and Health Survey (SADHS) was first conducted in 
1998 in a random sample of 13,802 subjects aged 15 years or older, of whom 76% were 
black people. The incidence of hypertension for the black South African population was 
21%. For those over 65 years of age, 50% to 60% were hypertensive (SADHS, 1998). 
More than 6 million South Africans suffer from high blood pressure, and this figure is 
still on the increase (Steyn K, et al, 2000), yet fewer than one out of every five people 
with high blood pressure receive treatment of any kind in South Africa. In many cases 
where people have been diagnosed with high blood pressure and they are receiving 
treatment, the patient’s high blood pressure is not controlled nearly well enough. If the 
situation continues and not enough actions are taken to prevent and effectively treat 
hypertension in South Africa, more people will die from heart-related conditions than 
from Aids in the near future (http://www.health24.com). Contrary to popular opinion, 
high blood pressure often occurs in younger people.  
 
2.1.5 The extent of the problem 
Several community studies done by the Medical Research Council (MRC) showed that 
one out of every four people between the ages of 15 and 64 suffer from high blood 
pressure. Unhealthy lifestyle habits and poor eating habits play a great role in the 
development of high blood pressure, according to Dr Krisela Steyn, MRC researcher and 
project leader of several studies concerning blood pressure (Steyn K, et al, 2000).  
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2.2 Risk factors for hypertension  
Risk factors for hypertension are factors that do not seem to be a direct cause of the 
disease, but seem to be associated in some way. Having a risk factor for hypertension 
makes the chances of getting the condition higher but does not always lead to 
hypertension. Also, the absence of any risk factors or having a protective factor does not 
necessarily guard people against getting hypertension.  
 
The list of risk factors for hypertension includes: 
Sodium intake: Excessive sodium intake is considered as an absolute and obvious risk 
factor of hypertension. Dahl first published scientific evidence for a positive association 
between salt consumption and blood pressure in the 1960’s (Dahl LK, 1961). He 
described a remarkable linear relationship between average sodium intake and prevalence 
of hypertension across five population groups. Since then, an abundance of evidence 
from observational studies among and within various populations have shown a positive 
relationship between sodium intake and arterial pressure in all age groups (MacGregor 
GA, 1983; Law MR and Frost CD, 1991; Campese, VM, 1994; Stamler J, 1997; Cutler 
JA, et al, 1997; Whelton PK, et al, 1998; Sacks FM, et al 2001).  
In addition, there has been increasing circumstantial evidence from population and basic 
science studies that dietary sodium may cause cardiovascular target organ injury through 
blood pressure-independent effects. Et-taouil et al (2001) reported that a high-sodium diet 
decreases aortic hyaluronan content and large artery compliance through blood 
pressure-independent mechanisms (Et-taouil, et al, 2001). Now high sodium intake is one 
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of the fastest and most common methods to induce hypertension in animal models 
(Garrett MR, 2002). 
 
Obesity: Obesity is a term applied to excess body weight with an abnormally high 
proportion of body fat (Grundy SM, 2002). Being overweight is a serious condition. 
There’s no doubt obesity is a significant risk factor to the development of hypertension. 
A large body of epidemiological data has supported a link between obesity and 
hypertension (Kannel WB, 1967; Bethesda MD, 1998; Eckel RH, et al, 1998). 
  
The pathophysiology of hypertension in obesity is complex and multifactorial and 
includes factors such as insulin, an overactive sympathetic nervous system, and so on. 
Though the mechanisms are complex, obesity is regarded to be characterized by 
maladaptive hemodynamics and abnormal responses to stress, and both defects could 
potentially contribute to hypertension (Nasser M, et al, 1999). 
 
Lifetime Risk of Hypertension: Lifetime risk statistics describes the long-term risk for 
developing hypertension in an individual, which is the probability of developing 
hypertension during the remaining years of life (either adjusted or unadjusted for 
competing causes of death). In both 55 and 65-year-old participants, the cumulative 
lifetime risk for the development of hypertension (at or above 140/90 mm Hg regardless 
of treatment) was 90% (Figure 2-1). Other studies showed that the age-related rise in 
SBP is primarily responsible for an increase in both incidence and prevalence of 
hypertension with increasing age (Franklin SS, et al, 1997).  
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Figure 2-1 Residual lifetime risk of hypertension in women and men aged 65 years.  
 
Reproduced from: Vasan RS, et al, 2002 
 
Alcohol intake: People believe that regular alcohol consumption can produce positive 
psychosocial effects and some beneficial effects on health, especially reduced 
atherothrombotic events and death. Excessive alcohol consumption produces the opposite 
effects and has been proven to be associated with cardiovascular disorders, including 
hypertension, coronary artery disease, and stroke (Maiorano G, et al, 1995; Fuchs FD, et 
al, 2001). MacMahon studied more than 30 cross-sectional epidemiologic studies and 
stated that an overwhelming majority of the studies had reported significant elevations in 
blood pressure in individuals who consumed excessive alcohol (MacMahon S, 1987).  
 
Caffeine intake: Caffeine may be the world’s most commonly used pharmacologic 
substance. Caffeine has been proven to cause mental stimulation and increases blood 
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pressure (Rainnie DG, 1994). Caffeine intake corresponding to 1 to 4 cups of coffee can 
increase systolic and diastolic blood pressure by 14 mm Hg and 13 mm Hg respectively 
in caffeine-withdrawn subjects (Robertson D, 1978) at rest or during mental or exercise 
stress (Sung BH, 1990). Its pressor effect is greater in subjects with hypertension (Hartley 
TR, 2000). In men, caffeine increases BP by increasing vascular resistance (Pincomb GA, 
1985), with no effect on cardiac output (Pincomb GA, 1991). In women who are regular 
caffeine consumers, the BP response is also sustained, but by greater cardiac output 
(Terry R, et al, 2004). 
 
Smoking: The American Heart Association (AHA) estimates that about one in five 
deaths from cardiovascular diseases are attributable to smoking, about 37,000 to 40,000 
nonsmokers die from CVD each year as a result of exposure to passive cigarette smoke 
(2002 Heart and Stroke Statistical Update). Individuals who smoke are two to six times 
more likely to develop coronary artery disease than nonsmokers. Smoking causes 
hardening of the arteries, which may increase blood pressure.  
 
2.3 Treatment for hypertension 
The goal of treatment for most patients is to lower the systolic blood pressure below 140 
mm Hg and the diastolic blood pressure below 90 mm Hg. Treatment for high blood 
pressure involves lifestyle modifications and drug therapy.  
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2.3.1 Lifestyle modifications 
A variety of lifestyle modifications have been shown, in clinical trials, to lower blood 
pressure (Ebrahim S and Smith GD, 1998) and to reduce the incidence of hypertension 
(Stevens VJ, et al, 2001). In many patients, particularly those whose blood pressure is 
moderately elevated, life style modifications alone may achieve treatment goals. Patients 
who require drug therapy may also reduce the frequency and doses of medications 
through life style modification. The following modifications in diet and physical activity 
should be carried out. 
 
? Weight loss in the overweight. It has been widely proved that overweight 
patients can reduce blood pressure by losing weight (Leiter LA, et al, 1999). 
Gradual weight loss through modified calorie intake and increased physical 
activity is a good approach.  
? Physical activity. Regular, moderate aerobic exercise can modestly decrease 
blood pressure and has many other beneficial effects (Hagberg JM, et al, 2000).  
? Salt (sodium chloride) restriction. Since excessive salt intake can contribute 
to increase blood pressure, it is strongly suggested to limit salt consumption. 
Generally, a reduction to no more than approximately 2.4 grams of salt per day 
will have a much greater effect and should become the long-term target for 
population salt intake worldwide (Barry D and Stephen H, 2007).  
? Limited alcohol intake. Moderate alcohol intake does not appear to cause 
hypertension. However, chronic heavy alcohol use elevates blood pressure (Xin 
X, et al, 2001). This may be the most common reversible cause of high blood 
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pressure (Maheswaran R, et al, 1991). Therefore, hypertension patients who 
drink alcohol excessively should reduce their consumption of alcohol.  
? A diet with increased fresh fruit and vegetables and reduced saturated fat 
content. Fresh fruit and vegetables contain rich and various vitamin and 
vegetable fibre, which can contribute to the elimination of deposit on the walls 
of blood vessel (Sacks FM, et al, 2001). They are much accessible for most 
communities and suggested to be a good life-long habit.  
 
Other lifestyle changes have not been found in multiple clinical trials to have a significant 
or lasting antihypertensive effect. These include calcium (Griffith LE, et al, 1999) and 
magnesium supplements (Kawano Y, et al, 1998), reduction in caffeine intake (Jee SH, et 
al, 1999), quit smoking, and a variety of techniques designed to reduce stress (Leiter LA, 
et al, 1999), which are mainly performed by massage or relaxation therapy. 
 
From the above it is clear that regardless of the blood pressure reading, all individuals 
should adopt appropriate lifestyle modifications. It is regarded as the foundation stone to 
prevent the prevalence of hypertension and cardiovascular diseases. The protective 
effects of modifying lifestyle include a reduction in the incidence of hypertension, heart 
attack and stroke, is likely to reduce cardiovascular morbidity and mortality. 
Furthermore, non-pharmacological therapy has much more advantages than drug therapy, 
such as no known harmful effects and it can improve the sense of well-being of the 
patient. Drug therapy on the other hand may cause adverse effects and reduce the quality 
of life in some patients.  
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2.3.2 Drug therapy 
Generally there are several typical drug classes used against hypertension in the 20th 
century. Since 1967 more than 20 randomized, controlled trials (RCTs) have compared 
diuretics, β -blockers, and calcium channel blockers (CCBs) against placebo in 
hypertensive patients (Collins R, et al 1990; Neal B, et al, 2000; Psaty BM, et al, 1997). 
Later a newer drug class, angiotensin-converting enzyme (ACE) inhibitors, which plays 
an important role in the drug therapy of hypertension and attracts more and more 
attention were developped. In 2000 ACE inhibitors were compared with CCBs in almost 
75,000 hypertensive patients and the related meta-analysis of data from the RCTs was 
published (Neal B, et al, 2000). For the endpoints of total cardiovascular mortality, the 
meta-analysis shows no significant convincing differences between drug classes or 
between the groups of old and new drugs. 
 
Many clinical trials show that some patients need to reduce their blood pressure to lower 
levels than previously recognized and will often require more than one drug (Hansson L, 
et al, 1998; Dahlof B, et al, 2002). To achieve the best objectives, ACE inhibitors are 
also used together with other drug classes, such as diuretic and CCBs (Gilderman L, et al, 
2005).  
 
2.3.3 Drugs in different populations 
Most drugs used to treat hypertension have also been evaluated for a number of specific 
indications. In addition, different classes may have different effect levels when treating 
the same disease. For regression of LVH, ACE inhibitors and CCBs was found to be 
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more effective than β-blockers and diuretics (Dahlof B, et al, 2002; Schmieder RE, et al, 
1998; Devereux RB, et al, 2001). Further comparative studies showed a greater reduction 
in proteinuria has been found with initial therapy with ACE inhibitors than with other 
classes (Brenner BM, et al, 2001; Agodoa LY, et al, 2001). Multiple placebo-controlled 
trials have shown significant reductions in proteinuria and a slowing of progression of 
renal damage in both non-diabetic and type-I diabetic nephropathies with ACE inhibitors 
(Jafar TH, et al, 2001).  
 
Moreover, certain drugs may logically be chosen for other reasons. For example, a 
diuretic or CCBs may lower blood pressure more in Africa-American and older patients 
than an ACE inhibitors or a β-blocker (Cushman WC, et al, 2000; Radevski IV, et al, 
2000). 
 
2.4 Mechanisms of ACE inhibition therapy 
 
2.4.1 Renin-Angiotensin-Aldosterone System (RAS) 
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Figure 2-2 The pathway of ACE inhibition in Renin-Angiotensin-Aldosterone 
system. 
 
Sites of pharmacologic blockade in the rennin-angiotensin-aldosterone system: 1) renin inhibitors, 2) ACE 
inhibitors, 3) angiotensin II type I receptor antagonists, 4) angiotensin II type II receptor antagonists. 
Reproduced from Garry PR and John HB, 2001. 
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The RAS plays an important role in regulating blood volume, arterial pressure, and 
cardiac and vascular function (Figure 2-2). While the pathways for the RAS have been 
found in a number of tissues, such as brain (Johnston CI, et al, 1992), blood vessel wall 
(Müller DN and Luft FC, 1998), etc, the most important site for renin release is the 
kidney. Sympathetic stimulation, renal artery hypotension, and decreased sodium 
delivery to the distal tubules stimulate the release of renin by the kidney. Renin is an 
enzyme that acts upon a circulating peptide substrate, angiotensinogen, which undergoes 
proteolytic cleavage to form the decapeptide angiotensin I (AI). Vascular endothelium, 
particularly in the lungs, has an enzyme, angiotensin converting enzyme (ACE), which 
cleaves off two amino acids to form the octapeptide, angiotensin II (AII).  
 
AII has several very important functions:  
? Constricts resistance vessels (via AII receptors) thereby increasing systemic 
vascular resistance and arterial pressure 
? Acts upon the adrenal cortex to release aldosterone, which in turn acts upon the 
kidneys to increase sodium and fluid retention 
? Stimulates the release of vasopressin (antidiuretic hormone) from the posterior 
pituitary which acts upon the kidneys to increase fluid retention 
? Stimulates thirst centers within the brain 
? Facilitates norepinephrine release from sympathetic nerve endings and inhibits 
norepinephrine re-uptake by nerve endings, thereby enhancing sympathetic 
adrenergic function 
? Stimulates cardiac hypertrophy and vascular hypertrophy 
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Therapeutic manipulation of this pathway is very important in treating hypertension and 
heart failure. ACE inhibitors and AII receptor blockers, for example, are used to decrease 
arterial pressure, ventricular afterload, blood volume and hence ventricular preload, as 
well as inhibit and reverse cardiac and vascular hypertrophy. 
 
2.4.2 ACE inhibitors 
ACE inhibitors are valuable agents for the treatment of hypertension, heart failure, and 
other cardiovascular and renal diseases. The cardioprotective effects of ACE inhibitors 
are mediated by blockade of both conversion of AI to AII and kinin hydrolysis, as 
displayed in Figure 2-2. A recent study shows that in AII-induced hypertension, the 
cardiac antifibrotic effect of ACE inhibitors is a result of the inhibition of 
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) hydrolysis, resulting in a decrease in 
cardiac cell proliferation (probably fibroblasts), inflammatory cell infiltration, TGF-beta 
expression, Smad2 activation, and collagen deposition (Peng H, et al, 2005). 
Elevated plasma renin is not required for the actions of ACE inhibitors, although ACE 
inhibitors are more efficacious when circulating levels of renin are elevated. As the RAS 
is found in many tissues mentioned above, ACE inhibitors may act at these sites in 
addition to blocking the conversion of angiotensin in the circulating plasma. 
 
2.4.3 Therapeutic Uses  
Hypertension.  ACE inhibitors are effective in the treatment of primary hypertension 
and hypertension caused by renal artery stenosis, which causes renin-dependent 
hypertension owing to the increased release of renin by the kidneys. Reducing 
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angiotensin II formation leads to arterial and venous dilation, which reduces arterial and 
venous pressures. By reducing the effects of angiotensin II on the kidney, ACE inhibitors 
cause natriuresis and diuresis, which decreases blood volume and cardiac output, thereby 
lowering arterial pressure. 
 
Some of the older literature indicated that ACE inhibitors (and angiotensin receptor 
blockers, ARBs) were less efficacious in African American hypertensive patients, which 
unfortunately led to lower utilization of these important, beneficial drugs in African 
Americans.  While it is true that African Americans do not respond as well as other 
races to monotherapy with ACE inhibitors or ARBs (Matthew RW, et al, 1995), the 
differences are eliminated with adequate diuretic dosing. Therefore, current 
recommendations from the 7th report of the Joint National Committee are that ACE 
inhibitors and ARBs are appropriate for use in African Americans, with the 
recommendation of adequate diuretic dosing to achieve the target blood pressure (Aram 
VC, et al, 2003). 
 
Heart Failure.  ACE inhibitors have proven to be very effective in the treatment of 
heart failure caused by systolic dysfunction, like dilated cardiomyopathy (Eichhorn EJ, 
1998). Beneficial effects of ACE inhibition in heart failure include: 
? Reduced afterload, which enhances ventricular stroke volume and improves 
ejection fraction.  
? Reduced preload, which decreases pulmonary and systemic congestion and 
edema.  
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? Reduced sympathetic activation, which has been shown to be deleterious in 
heart failure.  
? Improving the oxygen supply/demand ratio primarily by decreasing demand 
through the reductions in afterload and preload.  
? Prevents AII from triggering deleterious cardiac remodeling.  
 
Finally, ACE inhibitors have been shown to be effective in patients following myocardial 
infarction because they help to reduce deleterious remodeling that occurs post-infarction.  
 
2.4.4 Specific Drugs  
The first ACE inhibitor marketed, captopril, is still widely in use today.  Although newer 
ACE inhibitors differ from captopril in terms of pharmacokinetics and metabolism, all 
the ACE inhibitors have similar overall effects on blocking the formation of AII. ACE 
inhibitors include the following specific drugs:   
Benazepril  
Captopril  
Enalapril  
Fosinopril  
Lisinopril  
Perindopril  
Ramipril  
Trandolapril 
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2.4.5 Unwanted effects 
Although ACE inhibitors affect capacitance and resistance vessels and reduce cardiac 
load as well as arterial pressure, one should be aware of the existence of unwanted 
effects. For example, captopril was initially used in doses that, in retrospect, were 
excessive. In these large doses, it caused dry coughs, rashes, taste disturbance and heavy 
proteinuria (Ahmad M, et al, 2005). Currently dry coughs are still a common side effect 
of ACE inhibitors and remain the major limiting factor of their use. Secondly, despite the 
availability of useful non-drug therapy and potent medications, treatment is too often 
ineffective, mainly as a consequence of the patient’s lack of compliance with therapeutic 
regimens (WHO, 2003).  Moreover, because of limited resources, synthetic drug 
treatment may be not affordable to the majority of hypertensive patients. 
 
2.5 Medical Plants with antihypertensive effects 
2.5.1 Traditional medical plants 
A medicinal plant is any plant which provides health-promoting characteristics, 
temporary relief or symptomatic problems or has curative properties. 
(http://davesgarden.com) 
 
Medicinal plants play a very important role since the existence of human beings. As early 
as 2800 B.C., the first independent system about Traditional Chinese Medicine (TCM) 
appeared on the earth, which is called “The Medical Classic of the Yellow Emperor” 
(Zhu M, 2001). This book is written in the form of a dialogue in which the Yellow 
Emperor (the legendary first ancestor of the Chinese nation) discusses medicine with his 
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ministers and some well-known doctors. No researchers of TCM in China could escape 
knowing about this text. Till now over 40% of medicines prescribed in the United States 
contain chemicals derived from plants (http://www.nps.gov). Furthermore, most 
developing countries are endowed with vast resources of medicinal and aromatic plants, 
much of which are still under-explored, especially in the rural areas. 
 
Africa has a long and impressive list of medicinal plants that are used based on local 
knowledge. There are 70-80% of Africa’s population relies on medicinal plants 
(Cunningham AB, 1993). Considering of being precluded from the luxury of access to 
modern therapy, mainly for economic reasons, this number won’t change much now.  
All over, including Africa, it is claimed that the use of traditional plant medicines offer 
many advantages. 
 
The scientific literature relating medicinal plants to blood pressure is extensive and can 
be dated back to more than 100 years ago. With the development of technology, people 
do not settle for taking infusions or decoctions orally any more. They start to locate the 
effective components and look for the right doses. More and more traditionally used 
medicinal plants have been studied to investigate the principles or mechanisms of their 
blood pressure lowering effect. 
 
Medicinal plants, including Olive, Camellia, Claviceps purpurea, Coffea arabica 
(Bruneton J, 1995), Hawthorn, Linden blossom, Yarrow, Cramp bark and Valerian 
(http://www.healthy.net), are a broad range of remedies that have the observed effect of 
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lowering elevated blood pressure. They appear to work in a variety of ways, such as 
cardiac tonics, diuretics, nervines and anti-spasmodics (David LH, 2005). 
 
In South Africa, traditional medicine is an integral part of cultural life. It is estimated that 
between 12 and 15 million South Africans still depend on traditional herbal medicine 
from as many as 700 indigenous plant species (Meyer JJM, et al, 1996).   
 
The traditional use of wild olive in South Africa has lasted for hundreds of years (Walter 
HL, et al, 2003). The dried leaves are most often used, followed by the roots or the stem 
bark. The scientific study seems to start from 1960’s, which determined the main use of 
this plant as a hypotensive to lower blood pressure and to enhance renal function (Watt 
JM, et al, 1962). Researchers screened 20 Zulu medicinal plants and indicated that 6 of 
them have high level of ACE inhibition activities, including Adenopodia spicata, Dietes 
iridioides, Mesembryanthemum, etc (Andrew C, et al, 1999).  
 
2.5.2 Advantages and disadvantages of medicinal plant medicine 
Traditional medicinal plants are potential sources of new drugs, sources of cheap starting 
materials for synthesis of known drugs. It is claimed that the human body better accepts 
drugs derived from natural sources than synthetic substances invented in the laboratory 
(Muhizi, 2002). Furthermore, traditional plant medicines have fewer side effects when 
compared with synthetic products. 
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Traditional plant medicines also have some disadvantages. Plants from different 
geographic areas may have biologic diversity (Fabricant and Farnsworth, 2001). 
Secondly, for most traditional medicines, the specific constituents that cause a therapeutic 
effect is often not known. There exist many different constituent in the plant, and it is 
likely that they work together to produce the desired therapeutic effect. The exact 
combination of active ingredients is often the crucial problem for the traditional plant 
medicine development. 
 
Olives have traditionally been used for hundreds of years and more and more researches 
proved its lowering blood pressure effect, it should get our more attention on the 
mechanism and comparative effects with classic synthetic medicines 
. 
2.6 Current studies using olives 
Olives have many different species in different geographic areas. Among these olives 
species, O europaea, the origin of the cultivated olives, is very widespread in 
Mediterranean countries, Africa, the Arabian Peninsula, the Indian subcontinent and 
Asia.  
 
Previously, most studies were performed on O europaea. Studies on the active principles 
of the European olive leaf, the two secoiridoids oleuropein and oleacein, have been 
conducted since 1960. It was reported that the bitter glycoside oleuropein had a 
hypotensive, coronary dilating and antiarrhythmic action (Petkov V and Manolov P, 
1972). Recently, a bioassay-directed fractionation showed that another component of 
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European olive leaf, beta-(3, 4 dihydroxyphenyl) ethanol was a potent calcium-antagonist 
(Rauwald HW, et al., 1994). The isolate by fractionation from the olive leaf, secoiridoid 
oleacein, was reported to have distinct ACE inhibitory effect (Hansen K, et al., 1995) and 
anti-oxidant activity (Bruneton J, 1995).  
 
The antiarrhythmic activity of 95% ethanol, glycerine and ethanol:glycerine (50:50) 
extracts of European leaf and shoot has been demonstrated in the rat administrated 
intragastrically (IG) at doses of 25mg/kg, following aconite-induced arrhythmia (Cicosta, 
et al, 1990). In the same study, antihypertensive activity was demonstrated by 
glycerine:ethanol (50:50) extracts given IG to the rat at dosages of 125-250mg/kg, 
following desoxycorticosterone acetate-induced hypertension. Positive inotropic effects 
of 95% ethanol, glycerine and ethanol:glycerine (50:50) extracts were demonstrated in 
the rabbit at dosages of 5.0 mg/ml (heart).  
 
Spasmolytic activity of similar extracts was demonstrated in the guinea pig at doses of 
50mg/kg against vasopressin-induced coronary spasm and hypotensive activity in the rat 
at doses of 100mg/kg, given IG. Maximum hypotensive activity effect was seen 60-120 
minutes after administration of each extract. Positive chronotropic effects of 
glycerine:ethanol (50:50) extracts were noted, when given IG to the desoxycorticosterone 
acetate - induced hypertensive rabbit at a dose of 125mg/ml (Cicosta, et al, 1990).  
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Leaf decoctions or lyophilised extracts administered to the rat showed spasmolytic 
activity against phenylephrine-induced contractions, both in the presence of and without 
endothelium (Zarzuelo, et al, 1991).  
 
Antihypercholesterolaemic activity has been shown in rats given a daily dose (IG) of 
500mg/kg of a glycerine:ethanol leaf extract for 15 days. Activity was noted both in 
diet-induced and triton-induced hypercholesterolaemic animals (Pasquale D, et al, 1991). 
Some of the cardio-vascular effects noted for O europaea have been attributed to the 
secoiridoids oleuropein and oleacein (ACE inhibitory activity).  
Another study also indicates the antihypertensive effects of olive leaf extracts in vivo in 
the rat following IG administration of 50mg/kg of an 80% ethanol extract (Khayyyal, et 
al, 2002).  
 
Effects, including renal effects via diuretic activities (Capretti G. and Bonaconza E. 1949; 
Ribeiro RA, et al, 1988), antimicrobial activity (Grange et al, 1990; Anesini C and Perez 
C, 1993), effects on the endocrine system (Eskander et al, 1995), effects on the 
inflammatory response (Fehri B et al, 1996), as well as hepatic activity (Han Y.M et al, 
2001), have been published. 
 
Inside O europaea, several subspecies are recognized, one of which is the small-fruited 
subspecies africana (formaly O africana), which is mainly located in African regions. 
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Figure 2-3   O africana 
 
                  
2.6.1 Geographical distribution 
O africana are widespread in a variety of habitats, from forest and riverside bush to open 
grassveld, stony flats, mountain kloofs and rocky ledges throughout Southern Africa and 
northwards through east Tropical Africa into Eritrea (Figure 2-4).   
Figure 2-4 Distribution map of O africana 
 
From: Breitenbach VF, 1986 
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2.6.2 Major chemical constituents  
Figure 2-5 Major chemical constituents 
 
From: Somova LI, et al, 2003 
 
2.6.3 Medicinal uses 
Traditionally O africana was mainly used to lower blood pressure and to treat related 
cardiovascular diseases by using the dried leaves, sometimes the roots or the stem bark. 
Several other traditional uses have been recorded (Watt JM, 1962; Hutchings A, 1996; 
Iwu MM, 1993). Leaf infusions are used elsewhere as a lotion to treat eye infections or as 
a gargle to relieve sore throat; it is also taken internally as a remedy for colic or urinary 
tract infections. The powdered leaf is also used as a styptic. 
 
Much research have been done on O europaea (Trovato A, et al, 1993; Rauwald HW, et 
al, 1994; Al-Qarawi SA, et al, 2002; Khayyyal MT, et al, 2002). However, studies on O 
africana are seldom published. Recently, Somova LI and co-workers published their 
findings on O africana (Somova LI, et al, 2003 and 2004). They indicate that O africana 
leaves can prevent the development of severe hypertension and atherosclerosis of the 
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experimental animals in a dose 60 mg/kg b.w. for 6 weeks treatment. It provides an 
effective and cheap treatment of this particular, most common type of salt-sensitive 
hypertension in the African population. Osim EE, et al. (1999) investigated the effects of 
crude extracts of root and stem of O africana and concluded that the extracts lowered the 
blood pressure and heart rate in both normotensive and hypertensive rats (Osim EE, et al, 
1999). 
 
2.7 Research problems 
From section 2.6 it is clear to conclude from the above screening of previous studies that, 
although O africana has been observed to produce blood pressure lowering effects, the 
aqueous extract of O africana leaves has not been systematically tested. Considering that 
O africana is traditionally used with hot water, we consider the aqueous extract as very 
important. Moreover, does the aqueous extract of O africana produce better 
antihypertensive effect than synthetic medicine or not? It seems no such studies have 
been done yet. The most effective dose of aqueous extract has also not been determined. 
 
2.8 The Dahl Salt-Sensitive (DSS) and Salt-resistant (DSR) rats in 
hypertension research. 
The arterial pressure of some human hypertensives is very sensitive to the changes in 
sodium intake, they therefore have been classified as “salt-sensitive”. Since the number 
of salt-sensitive hypertensives is quite big (Myron HW, et al, 2001), it is necessary to 
choose salt-sensitive animal model to perform this study. 
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2.8.1 Dahl Salt-Sensitive (DSS) Rats  
The Dahl Salt-Sensitive rat may be the animal model of choice. The Dahl rat is one of the 
most widely studied models of hypertension with over 1600 references in the literature 
over the past 35 years. There is already evidence for the Dahl rats’ value in probing the 
genetics of human hypertension (Dahl LK, et al. 1961, 1962, 1963). Selective breeding of 
rats for susceptibility or resistance to the hypertensive effect of high salt intake was 
originally done in 1960s. Dahl’s study showed that chronic excess salt ingestion leads to 
sustained hypertension (Dahl LK, et al. 1961). Dahl and his partners then found that not 
all rats responded to salt with similar changes in blood pressure, then they selectively 
breed rats for susceptibility (S rats) or resistance (R rats) to the hypertensive effects of 
high salt (8% NaCl) diet. After only three generations of selective breeding, the S and R 
lines were clearly separated. The blood pressures of R rats were essentially similar on 
control or high salt diets, while S rats responded to salt with a pronounced increase in 
blood pressure (Dahl LK, et al. 1962). Thus, the two strains yielded an interesting model 
for the interaction of an environmental factor (salt) with genotype. 
 
2.8.2 Characteristics of Dahl rat 
The DSS rat can also be used to determine other related cardiovascular diseases like 
cardiac hypertrophy, heart failure, as well as insulin resistance, hyperinsulinemia, 
hypertriglyceridemia, hypercholesterolemia and nephropathy (Somova LI and Channa 
ML, 1999). 
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Secondly, the Dahl rat model has many characteristics in common with salt-sensitive 
humans, such as decreased NO production and a suppressed renin-angiotensin system 
(Chen PY and Sanders PW, 1993). 
 
Many studies that have used the DSS rat as their animal models, especially in those 
articles which studied the antihypertensive effects of olives, obtained great results and 
regarded the DSS rat as one of the standard hypertensive animal models (Yasuki K, et al, 
1997; Somova LI. et al, 2003). To use the same rat model will be helpful to determine the 
comparison of different extracts. 
 
2.8.3 Induction of hypertension 
Two methods are used to induce hypertension in this model: 
 
Firstly, via adding salt to the diet or water: 
Diet: 8% NaCl diet (high salt). Treating rats with a diet containing 8% NaCl is the main 
method to induce hypertension in the DSS model. It has been used for many years and is 
accepted by most of researchers (Inoko M, et al, 1994; Mozaffari M.S, et al, 2000). 
Previous studies show that LVH was observed 5 weeks after putting the DSS rats on a 
diet containing 8% NaCl  (DSS rats were fed a diet with 8% NaCl diet after the age of 6 
weeks), and left ventricle dilatation was marked at the 15-20 weeks. During the latter 
stage, the DSS rats showed labored respiration with left ventricle global hypokinesis. All 
the DSS rats died within 1 week by massive pulmonary congestion (Inoko M, et al, 
1994). 
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Water: 2%-4% NaCl in drinking water (high salt). The high salt diet is normally 
specially made, is not always easily available and is expensive. In recent years 
researchers indicated that treating animals with 2%-4% NaCl in drinking water also can 
induce hypertensive rat model (Li P, et al, 1998; Ojewole JAO, et al, 2006). Ojewole 
JAO and his team successfully induced hypertension in the DSS rat by giving 4% saline 
to drink. Rats with an arterial blood pressure of 170/120 mmHg and above were 
considered as hypertensive and used in that study. 
 
Secondly, via injection (intraperitoneally or intravenously): This method is seldomly used 
(Li XN, et al, 1998). 
 
2.9 Toxicity test 
The brine shrimp assay is a very useful tool to determine the toxicity for the isolation of 
bioactive compounds from plant extracts (Sam TW, 1993). Since formally published in 
1982, this method has been one of the most widely used tests (Meyer BN, et al, 1982; 
Alluri AK, et al, 2005). 
 
Lethal Concentration 50 (LC50) and Lethal Dose 50 (LD50) values are the common 
measurements of the acute toxicity. LC50 is the concentration needed to kill 50% of a 
sample population or hosts exposed (Stephen R and Joseph S, 2004). This measure is 
generally used when exposure to a chemical is through the animal breathing it in, while 
the LD50 is the measure generally used when exposure is by swallowing, through skin 
contact, or by injection. 
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2.10 Blood pressure measurements in rats 
Laboratory techniques used to measure blood pressure in rats involves both invasive and 
non-invasive techniques. The former includes radiotelemetry or methods in which the 
animal is anesthetized and several blood vessels are cannulated in order to allow for 
placement of a BP transducer and injection of drugs and saline. Non-invasive techniques 
include photoplethysmography, piezoplethysmography and volume pressure recordings. 
The invasive techniques are very accurate and are the gold standard used to compare the 
accuracy of non-invasive techniques. 
 
We used the CODA II non-invasive system, (Kent Scientific, Connecticut, USA). This 
system uses volume pressure technology. The volume pressure recording sensor uses a 
specially designed differential pressure transducer to non-invasively measure the blood 
volume in the tail. With these measurements there are no artifacts related to eg. ambient 
temperature and movement artifacts are minimal and greatly reduced. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Plant material 
Leaves of O africana were collected from trees growing on the campus of University of 
the Western Cape (UWC) in South Africa, between September and October 2004. They 
were identified and authenticated by Mr. Benny Mouers of the Department of Botany, 
UWC. Specimens for O africana bearing voucher numbers 4849 and 4850 were used in 
this project.  
 
3.1.1 Preparation of aqueous extract 
Fresh leaves, 4,630 g, were washed twice, air dried for 2 weeks and ground into a 
powder. Of the powder 3,310 g was used to prepare an aqueous extract.  
 
The aqueous extract was obtained by shaking the powder in distilled water and allowing 
it to stand for 24 hours. It was then filtered, using Whatman filter paper and evaporated to 
10% of its original volume at a temperature of 40℃, using a rotary evaporator. The 
reduced volume of the filtrate was first frozen overnight and then freeze dried for 24 
hours to obtain a fine powder. The powder was weighed and dissolved in a known 
volume of distilled water and then serially diluted. The aqueous extracts were stored at 4 
ºC until use. 
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3.2 Animals 
Dahl salt-sensitive (DSS) rats and control Dahl salt-resistant (DSR) rats were obtained 
from the University of Kwazulu-Natal, South Africa. Male rats (5 weeks old), weighing 
200–220g, were used. Rats were maintained in the Medical Bioscience Department 
animal house at UWC and housed in polyethylene cages with water and standard diet 
provided ad libitum for 2 weeks to allow the rats to acclimatize to the new environment. 
Animal room temperature was maintained at 26 ± 2℃, with constant humidity and a 12-h 
light/dark cycle. During the 2 weeks the rats were trained in the experimental procedure 
to prevent stress induced hypertension during the experiments. 
 
3.3 Drugs 
Captopril and nifedipine were obtained from a local pharmacy. Jelly and gelatin were 
purchased from a local supermarket. 
 
3.4 Blood pressure determination 
An automated computerized tail-cuff blood pressure monitor, the CODA II TM 
Non-Invasive Blood Pressure System (from Kent Scientific Corporation, Connecticut, 
USA) was used to record the blood pressure and heart rates of rats. 
 
Rats were placed in restraining holders with a nose cone to calm the animals. The 
restrainers were placed on a heating pad (32 ± 2℃) to warm the rat’s tail and maintain 
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blood flow to the tail. Animals were placed in the restrainers for at least 5 minutes before 
monitoring the blood pressure. 
Figure 3-1 Picture shows a rat in restraining holder ready for blood pressure 
determination. 
 
 
3.5 Toxicity Test  
The brine shrimp (Artemia salina) toxicity test was used to investigate the toxicity of the 
aqueous extract of O africana. The materials included brine shrimp eggs, sea water, Petri 
dishes, liquid pipettes, test compounds (O africana aqueous extract) and filter paper. 
 
3.5.1 Procedure  
Hatching of the brine shrimp: 
Brine shrimp eggs were obtained from a local pet shop. The standard procedure described 
by Meyer et al. (1982), was followed. The eggs were hatched in a 1L glass bottle filled 
with seawater. The sea water was filtered twice to get rid of any contaminants. The brine 
shrimp were kept under constant aeration at 25 ºC for 48 hours. After hatching, active 
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nauplii completely free from egg shells were collected by pipette. The nauplii were 
transferred into a shallow dish and a light was put on the side. The most active nauplii 
were chosen and used for the assay. 
 
Preparation of the plant material: 
To prepare a stock of O africana extract 20 mg of freeze-dried aqueous extract of O 
africana was dissolved in 2 ml of distilled water. From the stock solution, 5μl was 
sampled and directly pipetted on a circular filter paper disc (2 cm in diameter) in each of 
three Petri dishes. The Petri dishes with discs were briefly placed in the oven to allow 
evaporation of the distilled water and 5 ml sea water was added to each Petri dish to 
make up a concentration of 10μg/ml. From the stock solution 50μl was added to each of 3 
Petri dishes containing circular discs and the same procedure, as described above, was 
performed to attain a new concentration of 100μg/ml in each Petri dish. To obtain a 
concentration of 1000μg/ml, the above procedure was followed using 500µl of the stock 
solution in each Petri dish. 
 
Brine shrimp bioassay: 
Toxicity was determined by using three concentrations of O africana: 10, 100 and 
1000μg/ml. The test was performed in triplicate at each of the concentrations. To account 
for accidental deaths a control, without extract, was included. Twelve Petri dishes each 
containing a filter paper circular disc (2cm in diameter) were thus prepared as indicated 
below:   
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Table 3-1 Dish preparation for toxicity test 
Control 10 μg/ml 100 μg/ml 1000 μg/ml 
○ ○ ○ ○ 
○ ○ ○ ○ 
○ ○ ○ ○ 
“○”: dish. 
 
Ten active shrimp larvae were carefully transferred into each Petri dish by pipette. The 
Petri dishes were maintained at room temperature and constant lighting for 24 hours. The 
surviving larvae were counted after 24 hours and the percentage deaths at each dose were 
determined. Only those larvae that were immotile after being touched were considered 
dead.  
 
LC50 determination: 
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Concentration was plotted against the percentage mortality. In cases where deaths 
occurred in the control solution, the data were corrected using Abbott’s formula (Abbott, 
W.S, et al, 1925): 
% deaths= [(test- control)/control] × 100 
 
LC50 value was obtained from the best-fit line where the concentration of the extract 
caused 50% mortality in brine shrimp test. 
 
3.6 Induction of Experimental Hypertension 
The method for inducing experimental hypertension was similar to the way used by 
Ojewole JAO, et al (2005). All animals were fed normal laboratory chow. To induce 
hypertension animals had free access to water containing 2% NaCl (high salt group). 
Animals in the control group received normal tap water.  
 
The systolic and diastolic blood pressure and heart rate were recorded by a tail cuff using 
the CODA II TM Non-Invasive Blood Pressure System, as described above. 
 
3.7 Protocols  
3.7.1 Effect of salt supplementation on the blood pressure of DSS and DSR rats 
Blood pressure and heart rate were measured twice weekly in two groups (n=8 each) of 
DSS rats and two groups (n=8 each) of DSR rats. One group of DSS rats and one group 
of DSR rats received normal tap water (NS, normal salt/control groups) while another 
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group of DSS rats and DSR rats received 2% NaCl in the drinking water (HS, high salt 
groups).  
 
3.7.2 Effect of acute treatment with O africana 
3.7.2.1 Effect of single injection of O africana on normotensive rats 
Seven groups (n=6 each) of normotensive DSS rats were used for these experiments. Rats 
received a single injection of one of six different doses (10, 40, 75, 200, 1000 and 
1200mg/kg i.p.) of O Africana. The seventh group received normal saline by injection 
(i.p) and served as the control group. Systolic and diastolic blood pressures, as well as 
heart rate were monitored for 80 minutes after the injection. 
 
3.7.2.2 Effect of single injection of O africana on hypertensive rats 
Two groups (n=6 each) of DSS rats received 2% NaCl drinking water (high salt) for 2 
weeks to induce hypertension. At the end of the second week, one group received 
1000mg/kg of O africana extract by injection (i.p.), while the other group (control group) 
received normal saline by injection (i.p). Systolic and diastolic blood pressures, as well as 
heart rates were monitored for 150 minutes after the injection treatment. 
 
3.7.3 Effect of chronic treatment with O africana 
48 DSS rats were divided into 6 groups (n=8 in each group). One group received normal 
tap water (control group) and another received 2% NaCl in the drinking water (HS 
group). A third group received 2% NaCl + extract (1000 mg/kg/day) in the drinking 
water. To ensure that the rats received the correct dosage of the extract two animals were 
housed per cage. The average volume of water consumed by the rats per day was 
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measured twice weekly in order to adjust the captopril content in the water if necessary. 
Animals were also weighed twice weekly. Group four received 2% NaCl in the drinking 
water and were given 50 mg/kg captopril per day (HS + captopril group). Group five 
received water containing 2% NaCl and were given 10 mg/kg nifedipine per rat per day 
(HS + nifedipine group). Captopril and nifedipine were administered in blocks containing 
gelatine and jelly. Group six received 2% NaCl in the drinking water in the first week and 
were given 2% NaCl + extract (1000 mg/kg/day) in the drinking water in the second 
week (HS + extract in 2nd week).  
Blood pressure and heart rates were monitored prior to treatment and thereafter twice per 
week for two weeks. 
 
3.7.4 Angiotensin converting enzyme inhibition activity of O africana 
In order to determine whether the O africana extract has ACE inhibitor properties two 
types of biochemical determinations were performed. Firstly, ACE inhibitors can reduce 
blood pressure by reducing the level of ACE. The level of ACE in blood is described in 
an addendum to the thesis. Secondly, here we determined the angiotensin II level in the 
plasma to illustrate ACE inhibiting properties of the extract 
 
After two weeks treatment as described in section 3.7.3 rats were fasted overnight. The 
next day the animals were anesthetized with sodium pentobarbital (50 mg /kg i.p.). The 
chests were quickly opened and blood was collected from the trunk.  After 10 minutes 
centrifugation at 5 000g, plasma was collected and stored at -20 ºC for determination of 
AII levels. 
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To extract AII plasma samples were defrosted and brought to room temperature. Phenyl 
cartridges were pre-washed with 1 ml of methanol, followed by 1 ml of water. Two ml of 
plasma was passed through the cartridge. The cartridge was again washed with 1 ml of 
water. Angiotensin II peptides were eluted from the cartridge with 0.5 ml of methanol. 
The methanol was then evaporated to dryness in a fume hood. 0.5 ml of EIA buffer was 
added and each sample centrifuged at 3000 g for 10 minutes at 4°C. AII was determined 
by an EIA assay (Société de Pharmacologie et d'Immunologie-BIO, France) according to 
the manufacturer’s instructions. The plate was read at 405 nm. 
 
3.8 Statistical analysis 
Results are shown as the mean±SEM. Two groups were compared using a Student’s 
t-test. Multiple groups were compared by ANOVA by the Bonferroni post hoc tests. P< 
0.05 is considered significant. All tests were performed by using the SPSS V13.0 
statistical package. 
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CHAPTER 4 
RESULTS 
 
4.1 Percentage yield of the extract 
For the aqueous extract, 3,310 g of the dried ground plant material was used and the 
extract powder obtained after freeze drying was 86.2 g thus, producing a 2.6% yield.  
 
4.2 Brine shrimp toxicity test 
The brine shrimp toxicity test showed that the aqueous extract of O africana has low 
toxicity with LC50 >5000 µg/ml (See Table 4-1 and Figure 4-1). 
 
Table 4-1 Brine shrimp death during toxicity testing 
 
% Deaths LC50 µg/ml 
  10 µg/ml 100 µg/ml 1000 µg/ml   
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Control 0 0  0           
Aqueous 7 17  40  >5000 
No of dead brine shrimp is indicated as a percentage of the total no of brine shrimp present at each 
concentration. 
 
 
 
Figure 4-1 Toxicity of aqueous extract of O africana. 
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4.3 Water intake 
Prior to salt loading the water intake for the rats was 35 ± 2 ml/day per rat. At the end of 
the 2 week experimental period the water intake of rats receiving normal tap water was 
36 ± 2 ml/day per rat, while the rats receiving 2% NaCl in drinking water drank 40 ± 2 
ml/day per rat, which was significant more than control (p<0.001). 
 
4.4 Effect of salt loading on SBP, DBP and HR of DSS and DSR rats 
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The systolic and diastolic blood pressure of rats receiving normal tap water (NS) or 2% 
NaCl (HS) in the drinking water were monitored for up to 7 weeks. For the first two 
weeks all animals received normal tap water and were acclimatized to the experimental 
procedure. From week 3 onwards rats received either normal tap water (NS) or 2% NaCl 
(HS) in the drinking water. At the end of the training period SBP, DBP and HR were 
within the normal range for all groups (Table 4-2-1, 4-2-2 and 4-2-3). The following are 
considered normal values for rats: BP = 130/90 (http://www.williams.edu/) and HR = 350 
- 450 beats per minute (Piotr J and Jolanta Z, 2001). 
 
Figure 4-2 Picture shows a representative recording obtained when blood pressure 
was measured with the CODA IITM system. 
 
 
High salt treatment produced a quick and significant increase in SBP (130.83 ± 2.66 to 
163 ± 2.79, p< 0.001) and DBP (89.50 ± 2.81 to 119.33 ± 3.47, p< 0.001) in the 
salt-sensitive rats after 1 week, and the these values continued to increase in the second 
week of treatment. Heart rate was also significantly increased (Table 4-2-3: 423.33 ± 
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3.00 VS 413.38 ± 8.58 after 1 week; 429.67 ± 10.35 VS 406.88 ± 4.16 after 2 weeks, 
p<0.05), but the value remained within the normal range.  By the end of the second 
week the animals were weak and we decided to terminate the experiment. 
 
In the DSR rats salt loading produced a significant increase in SBP after one week and 
the value continued to increase in the second week (Table 4-2-1, p< 0.05 to 0.001). 
Diastolic pressure and HR remained unchanged. 
 
In DSR rats receiving normal tap water DBP and HR remained constant throughout the 
experimental period. Systolic pressures record increased slightly in week 5 and 6 (133.38 
± 1.74 and 136.13 ± 2.11 Table 4-2-1), but the value was again normal in week 7. 
 
DSS rats receiving normal tap water showed a slow but significant increase in SBP and 
DBP over the experimental period (SBP 180.63 ± 4.81 VS 130.83 ± 2.66; 133.28 ± 1.25 
VS 89.50 ± 2.81, p< 0.001); the values, however, remained lower than in the 
corresponding HS group. 
 
Table 4-2-1. Average Weekly Systolic Blood Pressure 
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Values shown as Mean ± SEM. Numbers in brackets indicates the number of animals (n) in each group. 
Blood pressure is given in mmHg.  
NS = normal salt; HS = HS; 
- Salt loading with 2% NaCl; 
 *: p<0.05; **: p<0.01; ***: p<0.001 (Significance is relative to week 2 data) 
 
 
 
 
 
Table 4-2-2 Average Weekly Diastolic Blood Pressure 
 
Values shown as Mean ± SEM. Numbers in brackets indicates the number of animals (n) in each group. 
Blood pressure is given in mmHg 
NS = normal salt; HS = HS; 
- Salt loading with 2% NaCl; 
 *: p<0.05; **: p<0.01; ***: p<0.001 (significance is relative to week 2 data) 
 
 
 
Table 4-2-3 Average Weekly Heart Rate 
 
Strain / 
Week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 
DSS NS 
(8) 
128.25 
± 0.98 
127.38 
 ± 1.38 
131.75 
 ± 1.97 
149.00  
± 2.05***
161.50  
± 2.90***
169.88  
± 3.98*** 
180.63  
± 4.81***
DSR NS 
(8) 
120.88 
± 1.13 
128.13  
± 1.66 
129.38  
±1.54 
129.63  
± 1.69 
133.38  
± 1.74* 
136.13  
± 2.11** 
131.25  
± 2.30 
DSS HS 
(6) 
126.83 
± 2.68 
130.83  
± 2.66 
163.00  
± 2.79***
204.83  
± 4.13***
DSR HS 
(8) 
120.86  
± 1.32 
127.43  
± 2.31 
136.29  
± 1.80* 
142.14  
± 2.14***
Strain / 
Week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 
DSS NS 
(8) 
91.13  
± 2.00 
91.63  
± 1.63 
90.75  
± 1.71 
109.13  
± 2.43***
 116.13  
± 4.23***
125.63  
± 1.93*** 
133.38  
± 1.25***
DSR NS 
(8) 
86.38  
± 2.87 
89.38  
± 2.42 
91.50  
± 1.48 
87.63   
± 2.52 
90.13  
± 1.30 
90.38  
± 1.34 
90.38  
± 1.89 
DSS HS 
(6) 
86.17  
± 2.09 
89.50  
± 2.81 
119.33  
± 3.47***
145.00  
± 2.58***
DSR HS 
(8) 
88.57  
± 1.21 
86.14  
± 3.38 
91.86  
± 2.11 
93.00  
± 2.46 
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Values shown as Mean ± SEM. Numbers in brackets indicates the number of animals (n) in each group. 
Heart rate is given in beats per minute 
NS = normal salt; HS = HS; 
- Salt loading with 2% NaCl; 
 *: p<0.05; **: p<0.01; ***: p<0.001 (significance is relative to week 2 data) 
 
 
 
4.5 Effect of acute treatment with O africana 
4.5.1 Normotensive experiments: Single injection of O africana aqueous extract on 
normotensive rats 
The SBP, DBP and HR of normotensive DSS rats before injection of the extract were: 
130.83 ± 2.66 mmHg, 89.50 ± 2.81 mmHg and 422.17 ± 7.43 respectively. Injection of 
saline did not significantly influence SBP or DBP. Although fluctuations in HR was 
observed, it was not significant.  
 
Graded doses of aqueous extracts of O africana (40 to 75 mg/kg) produced a mild fall in 
systolic and diastolic blood pressure (p＜0.05 in comparison with control). In contrast, 10 
mg/kg of the extract did not produce any significant lowering of systolic or diastolic 
blood pressure in comparison with the pretreatment value (Table 4-3-1 and 4-3-2). 
Strain / 
Week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 
DSS NS 
(8) 
403.75  
± 3.99 
402.63  
± 17.31 
413.38  
± 8.58 
406.88  
± 4.16 
 417.00  
± 14.42 
424.75  
± 13.00 
418.63  
± 3.43 
DSR NS 
(8) 
400.25  
± 8.29 
413.25  
± 9.21 
397.75  
± 10.49 
403.63   
± 6.51 
394.25  
± 11.56 
418.25  
± 7.67 
411.50  
± 2.77 
DSS HS 
(6) 
407.50  
± 6.91 
414.67  
± 6.75 
423.33  
± 3.00* 
429.67  
± 10.35* 
DSR HS 
(8) 
407.14  
± 4.88 
403.29 
± 9.38 
403.14  
± 9.97 
416.43  
± 8.41 
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At higher doses, the O africana extract produced a greater and quicker significant 
lowering of systolic and diastolic blood pressure compared to the lower doses (p<0.05). 
At a dose of 1000mg/kg, the aqueous extract of O africana reduced the systolic and 
diastolic blood pressure to 87.67 ± 2.59 and 57.17 ± 1.93 mmHg respectively. At a dose 
of 1200 mg/kg, blood pressure was reduced faster than in the dose of 1000mg/kg (13.50 
± 0.67 VS 15.00 ± 0.45 min in SBP and 13.33 ± 0.76 VS 16.17 ± 1.11 min in DBP, 
p<0.001), but also came back to previous level quicker (SBP in 35.33 ± 2.23 VS 56.67 ± 
1.63 mins and DBP in 35.17 ± 1.80 VS 55.17 ± 3.15 mins, p<0.001, Figure 4-3-1 and 
4-3-2). We thus chose to administer O africana at a dose of 1000 mg/kg/day in 
experiments in which O africana was administered over a prolonged period of time. 
 
Injection of the O Africana extract affected heart rate (p<0.05) only when injected at the 
higher doses (200, 1000 and 1200 mg/kg). The effect was not as lasting as the blood 
pressure lowering effect (Figure 4-3-3). 
 
Table 4-3-1 Effect of different doses of O africana, injected in a single dose, on 
systolic pressure of normotensive rats. 
Extract conc. 
(mg/kg) 
Max reduction 
(mmHg) 
% of reduction Reaction start 
time (min) 
Lasting time 
(mins) 
10 6.50 ± 1.34 4.97 ± 0.99 n/a n/a 
40 13.67 ± 3.72 10.53 ± 2.90 31.33 ± 0.56 16.67 ± 1.05 
75 22.17 ± 3.68** 16.96 ± 2.72** 27.33 ± 0.92*** 21.00 ± 1.39 
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200 28.83 ± 3.94*** 22.08 ± 2.81*** 24.50 ± 0.72*** 35.00 ± 1.48*** 
1000 42.33 ± 2.76*** 32.54 ± 2.03*** 15.00 ± 0.45*** 56.67 ± 1.63*** 
1200 26.50 ± 2.92*** 20.32 ± 2.11*** 13.50 ± 0.67*** 35.33 ± 2.23*** 
Values are shown as Mean ± SEM; n=6 in each group 
n/a: not available; *: p<0.05; **: p<0.01; ***: p<0.001 
 
 
 
 
 
 
Figure 4-3-1: Effect of different doses of O africana extract, administered as a single 
injection, on systolic blood pressure of normotensive rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001(relative to saline injection); n=6 in each group 
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Table 4-3-2. Effect of different doses of O africana extract, injected as a single dose, 
on diastolic blood pressure of normotensive rats. 
Extract conc. 
(mg/kg) 
Max reduction 
(mmHg) 
% of reduction Reaction start 
time (mins) 
Lasting time 
(mins) 
10 10.83 ± 2.39 11.06 ± 2.44 n/a n/a 
40 13.67 ± 7.54 13.94 ±7.69 29.17 ± 1.25 16.33 ± 0.99 
75 21.33 ± 7.76 21.77 ± 7.62 25.50 ± 1.18 23.83 ± 0.79 
200 32.00 ± 5.22** 32.65 ± 5.32** 26.50 ± 1.78 38.17 ± 1.72*** 
1000 36.50±3.25** 37.25 ± 3.32** 16.17 ± 1.11*** 55.17 ± 3.15*** 
1200 34.67 ± 2.81** 40.79 ± 3.31** 13.33 ± 0.76*** 35.17 ± 1.80*** 
Values are shown as Mean ± SEM; n=6 in each group 
n/a: not available; *: p<0.05; **: p<0.01; ***: p<0.001 
Figure 4-3-2: Effect of different doses of O africana extract, administered as a single 
injection, on diastolic blood pressure of normotensive rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001 (relative to saline injection):  n=6 in each group 
 
 
Figure 4-3-3: Effect of different doses of O africana extract, administered as a single 
injection on the heart rate of normotensive rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001 (relative to saline injection); n=6 in each group 
 
4.5.2 Hypertensive Experiments: Single injection of O africana aqueous extract on 
hypertensive rats 
The SBP and DBP of hypertensive DSS rats before injection of the extract or saline were: 
204.83 ± 4.13 mmHg and 145.00 ± 2.58 mmHg respectively. 
 
Graded volumes of normal saline, equivalent to the volumes of extract injected, did not 
significantly lower SBP or DBP (Figure 4-4-1 and Figure 4-4-2). At a dose of 
1000mg/kg, the O africana extract reduced SBP by 76.25 ± 2.38 mmHg (p< 0.001) 
compared to saline injection (control). Diastolic pressure was reduced from 137.00 ± 4.43 
to 83.38 ±  2.65 mmHg (p<0.001). The reduction in SBP and DBP was significantly 
(p=0.001) better in the hypertensive rats compared to the normotensive rats (SBP in 
 
 
 
 
 55
76.25 ± 4.40 VS 42.33 ± 2.76; DBP in 53.63 ± 5.53 VS 36.50 ± 3.25; Figure 4-4-3 and 
Figure 4-4-4). 
 
 
 
 
 
 
 
 
 
 
Figure 4-4-1 Effect of injection of 1000mg/kg O africana aqueous extract on systolic 
blood pressure in hypertensive DSS rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001 ; n=6 in each group 
 
Figure 4-4-2 Effect of injection of 1000mg/kg O africana extract on diastolic blood 
pressure in hypertensive DSS rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001; n=6 in each group 
Figure 4-4-3 Reduction in SBP in the hypertensive rats and normotensive rats. 
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Figure 4-4-4 Reduction in DBP in the hypertensive rats and normotensive rats. 
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Injection of the extract reduced HR significantly (p<0.001) after 25 minutes, an effect 
that lasted 15 minutes (Figure 4-4-5). 
 
Figure 4-4-5 Effect of injection of 1000mg/kg O africana aqueous extract on heart 
rate on hypertensive DSS rats. 
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*: p<0.05; **: p<0.01; ***: p<0.001; n=6 in each group 
 
4.6 Effect of chronic treatment with O africana extract  
Figure 4-5-1 shows that the SBP in the HS DSS group was 163.00 ± 2.78 mmHg after 1 
week and 204.83 ± 4.14 mmHg after 2 weeks of salt loading.  Diastolic pressure over 
the same period increased to 119.33 ± 3.47 and 145.00 ± 6.33 mmHg, respectively.  
 
O africana extract (1000 mg/kg/day) prevented the increase in SBP or DBP (Figure 
4-5-1 and 4-5-2) At the end of the 2nd week, the O africana extract decreased the 
systolic blood pressure to 128.88 ± 2.36 mmHg, which is not only significant lower than 
the high salt group (p<0.001), but also not significant from control group (128.88 ± 2.36 
VS 127.38 ± 1.69 mmHg, p>0.05). 
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The antihypertensives captopril (50 mg/kg/day) and nifedipine (10 mg/kg/day) also 
prevented an increase in SBP and DBP during salt loading of DSS rats (Figure 4-5-1). At 
the doses used, both the O africana extract and captopril had better blood pressure 
lowering effects on SBP than nifedipine (extract 128.88 ± 2.36, captopril 134.38 ± 2.30 
VS nifedipine 141.25 ± 2.34 mmHg), no significant difference was observed between the 
O africana extract and captopril.  
 
To determine whether the O africana can be used to effectively treat hypertension rats 
were given 2% NaCl in the drinking water for 1 week before they were treated with the 
extract. Systolic blood pressure was increased significantly (p<0.001) after 1 week salt 
loading (164.75 ± 2.30 VS 131.75 ± 1.31 mmHg). The SBP did not differ with the high 
salt group (164.75 ± 2.30 VS 163.00 ± 1.97 mmHg, p>0.05). After 1 week’s treatment 
with extract, the SBP was reduced back to the control level (133.25 ± 1.94 VS 127.38 ± 
1.69 mmHg, p>0.05), which was significantly lower than high salt group (p<0.001) 
(Figure 4-5-1).  
 
 
 
 
Figure 4-5-1 Effect of chronic treatment with O africana, captopril and nifedipine 
on systolic pressure of salt loaded DSS rats. 
 
 
 
 
 60
40
60
80
100
120
140
160
180
200
220
0 1 2Weeks
Sys
tol
ic 
blo
od 
pre
ssu
re 
(mm
Hg)
Cont r ol
Tr eat ed wi t h sal t
Tr eat ed wi t h sal t  and ext r act
Tr eat ed wi t h sal t  and Capt opr i l
Tr eat ed wi t h sal t  and Ni f edi pi ne
Tr eat ed wi t h sal t  and ext r act ( 2nd wk)
 
***: p<0.001 compared to high salt group; ·: p<0.05 compared to corresponding to week 0 group;  
…: p<0.001 compared to corresponding to week 0 group; NS-C: not significant in comparison with control; 
NS-S: not significant in comparison with high salt group. n=8 in each group. 
 
Salt loading for 2 weeks increase DBP from 89.50 ± 4.60 to 145.00 ± 6.86 mmHg. O 
africana extract (1000 mg/kg/day) prevented the increase in DBP. In fact, the DBP was 
significantly reduced (85.63 ± 2.49 VS 145.00 ± 6.86 mmHg, p<0.001; Figure 4-5-2). 
Both captopril and nifedipine also prevented the increase in DBP during salt loading 
(Figure 4-5-2). 
 
Diastolic blood pressure following salt loading for 1 week was 120.38 ± 4.72 mmHg. 
After a week of treatment with O africana extract, DBP was significantly reduced to 
93.75 ± 5.18 mmHg (p<0.001). This value was not significant from the initial value 
(91.63 ± 1.63 mmHg; p>0.05). 
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Figure 4-5-2 Effect of chronic treatment with O africana, captopril and nifedipine 
on diastolic pressure of salt loaded DSS rats. 
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***: p<0.001 compared to high salt group; ·: p<0.05 compared to corresponding to week 0 group;  
…: p<0.001 compared to corresponding to week 0 group; NS-C: not significant in comparison with control; 
NS-S: not significant in comparison with high salt group. n=8 in each group. 
 
The HR was 429.67 ± 11.75 beats per minute after 2 weeks of salt loading. O africana 
decreased the HR to 379.50 ± 8.57 beats per minute (p<0.001). This level was also 
significant lower than in the control group. Similar results were obtained in the captopril 
treated group (387.25 ± 3.68 beats per minute; p<0.001) and the nifedipine treated group 
(394.75 ± 5.01 beats per minute; p<0.001).The HR in all treatment groups were not 
significant from the values at the start of the experiment (p>0.05) (Figure 4-5-3).  
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Similar to SBP and DBP, HR in salt loaded animals was reduced after 1 week treatment 
with O africana extract (396.50 ± 15.16 beats per minute, p<0.001). Although changes in 
HR were noted, the HR remained within in normal range. 
 
Figure 4-5-3 Effect of chronic treatment with O africana extract, captopril and 
nifedipine on heart rate of salt loaded DSS rats. 
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***: p<0.001 compared to high salt group; ·: p<0.05 compared to corresponding to week 0 group;  
NS-C: not significant in comparison with control; NS-S: not significant in comparison with high salt group. 
n=8 in each group. 
 
4.7 Plasma Angiotensin II levels 
The plasma AII level of DSS rats in the control group (no salt loading) was 62.31 ± 1.18 
pg/ml, as shown in Figure 4-6. Following 2 weeks salt loading the plasma AII levels 
reached to 270.83 ± 9.76 pg/ml. Administration of O africana extract (1000mg/kg/day) 
prevented the increase in plasma AII level (13.57 ± 0.62 pg/ml, p<0.001, Figure 4-6). 
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The ACE inhibitor, captopril, also prevented the increase in plasma AII level (32.06 ± 
2.97 pg/ml, p<0.001, Figure 4-6). AII levels in the nifedipine treated group did not differ 
from that of the salt loaded group (265.80 ± 4.90 VS 270.83 ± 9.76 pg/ml; p>0.05). 
 
Both the O africana extract and captopril decreased the plasma AII levels to values below 
control (p<0.001, Figure 4-6). The plasma AII level following administration of the O 
africana extract was also significantly lower than obtained with captopril administration 
(p<0.01, Figure 4-6). 
 
Figure 4-6 Effect of O africana, captopril and nifedipine on plasma AII levels in salt 
loaded DSS rats 
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***: p<0.001 compared to high salt group; …: p<0.001 compared to control. n=7 in each group. NS-S: not 
significant in comparison with high salt group 
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CHAPTER 5 
DISCUSSION 
 
Olea africana, drunk as a tea, has been used to treat hypertension in Africa for many 
years (Breitenbach VF, 1986), yet not many studies have been done to determine the 
scientific basis of its use.  Furthermore, previous studies on the antihypertensive effects 
of O africana involved the use of either ethanol extracts (Somova LI, et al, 2003) or an 
aqueous extract from the roots and stems (Osim EE, et al, 1999) of the plant. This may be 
the first scientific report on the antihypertensive effect of an aqueous extract from the 
leaves of O africana. The leaves are the part of the plant most often used by traditional 
users (Breitenbach VF, 1986). 
 
It is argued that O africana causes blood pressure lowering effect by modifying the RAS, 
probably by acting as an ACE inhibitor. This study investigated the changes in the RAS 
during treatment via determining the angiotensin II levels in the blood and comparing it 
with the values obtained with the ACE inhibitor captopril, and nifedipine which is not an 
ACE inhibitor. 
 
5.1 Toxicity of the O africana extract 
Our results indicate that the plant extract has a very low toxicity (LC50 > 5000 µg/ml). 
We are thus satisfied that the dose of the extract used in our chronic treatment 
experiments is not toxic to the rats. 
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5.2 Induction of hypertension in the rat model by addition of salt to the 
drinking water 
Most studies in which the DSS rat is used to study hypertension, the animals are fed a 
high salt diet (8% NaCl in the diet) (Inoko M, et al, 1994; Mozaffari M.S, et al, 2000). It 
is undoubtedly a well established model that is well characterized. It does however 
require the use of synthetic diets which has to be specially formulated and is expensive. 
The time required before hypertension is achieved is at least 5 weeks (Inoko M, et al, 
1994). 
 
In this study hypertension was induced by adding 2% NaCl to the drinking water. This 
technique was first published by Ojewole JAO, et al (2003). In our experiments all DSS 
rats given 2% NaCl in the drinking water were hypertensive after only one week (Table 
4-2-1  and Table 4-2-3), The systolic pressure increased quickly and significantly from 
130.83 ± 2.66 mmHg to 163.00 ± 2.79 mmHg (p<0.05) and the diastolic pressure from 
89.50 ± 2.81 mmHg to 119.33 ± 3.47 mmHg (p<0.05). After 2 weeks of high salt 
treatment, these levels increased to reach 204.83 ± 4.13 mmHg and 145.00 ± 2.58 mmHg 
respectively, which is about 56.9% higher than normal blood pressure level and 25.2% 
(p<0.01) higher than after one week’s treatment.  
 
It was observed that at the end of 2 weeks of salt loading, all DSS rats were trembling 
and seemed very weak. Much more urine was discharged, compared to the normotensive 
animals, so that the bedding was often wet and had to be changed more frequently. 
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Normotensive rats in other groups were still active and didn’t show such weakness. 2 of 8 
DSS rats receiving salt in the drinking water died after 2 weeks, which is the reason that 
the data was recorded only from 6 rats in the DSS HS group. The rats in the DSS HS 
group probably developed heart failure or other serious cardiovascular diseases by the 
end of 2 weeks of salt loading. This is in comparison with the 8% NaCl dietary model 
where the rats develop LVH after about 5 weeks and heart failure after about 9-12 weeks 
(Inoko M, et al, 1994).  
 
An interesting finding is that the DSS group receiving normal tap water (i.e. normal salt) 
also became hypertensive after 4 to 5 weeks with systolic pressure increasing to over 160 
mmHg after 5 weeks. This may be because of some genetic drift in the colony since it is 
quite an old colony. On the contrary, the blood pressure of the DSR rats did not increase 
significantly. 
 
As indicated earlier, the DSS rats receiving 2% NaCl in the drinking water became weak 
after only 2 weeks. It can thus be argued that the salt content of the water should be 
reduced. In previous experiments of this nature in which DSS rats were used, the water 
salt content was as high as 4% (Ojewole JAO, et al, 2006). The rapid deterioration of the 
rats in our experiments can perhaps be due to the fact that also the DSS rats receiving 
normal tap water developed hypertension after a few weeks. It is thus necessary to 
monitor the rate at which hypertension develops closely in future experiments, especially 
if one also wants to study the progressive  deterioration from hypertension to LVH and 
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subsequent heart failure. It might then be necessary to reduce the salt concentration in the 
water to 1%. 
 
5.3 Effect of acute treatment with O africana in normotensive rats 
Intraperitoneally administration of the aqueous extracts of O africana leaves caused an 
immediate and dose dependant fall in both systolic and diastolic blood pressure, as well 
as heart rate in normotensive rats. The administration of equivalent volumes of normal 
saline, used as control for the extract, had no significant blood pressure or heart rate 
lowering effect. The decrease in blood pressure and heart rate can thus not be attributed 
to blood volume changes upon injection.  
 
All doses of aqueous extract of O africana leaves produced significant blood pressure 
and heart rate lowering effect (p<0.05 to 0.01) in normotensive rats, except the lowest 
dose (10mg/kg). The percentage reduction in systolic blood pressure differs from 13.07 
(40 mg/kg) to 34.02 (1000 mg/kg) from the lower doses to higher doses. The lasting time 
of the effect was from 15 to 55 minutes respectively, which indicates that aqueous extract 
of O africana leaves caused a dose dependant lowering effect of systolic blood pressure 
and heart rate.  
 
Although at doses of 40, 75 and 200 mg/kg, mean systolic and diastolic blood pressure 
was reduced significantly (p<0.05), it was observed that the maximum effect occurred at 
dose of 1000 mg/kg (87.67 ± 2.59 and 57.17 ± 1.93 mmHg), while the quickest lowering 
effect occurred at dose of 1200 mg/kg (13 mins). Figure 4-3-1 – Figure 4-3-3 show that 
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though the dose of 1000 mg/kg did not decrease the systolic pressure as rapidly as the 
1200 mg/kg (15 VS 13 mins), it reduced the blood pressure to the lowest level, as well as 
heart rate. Furthermore, the decrease in systolic pressure and heart rate was maintained 
for a longer period of time compared to the dose of 1200 mg/kg (Table 4-4-1). We thus 
concluded that the dose of 1000 mg/kg caused a more stable lowering effect on systolic 
blood pressure.  
 
A previous study (Osim EE, et al, 1999) reported that the aqueous extract from the roots 
and stems of O africana have a significant lowering effect on mean blood pressure at 
doses of 200 mg/kg and 1000 mg/kg (oral treatment). Our study suggests that the dose of 
1000 mg/kg should be the maximum effective concentration of aqueous extract of O 
africana.  
 
5.4 Effect of acute treatment with O africana in hypertensive rats 
In most cases, drugs are used to treat hypertensive patients, not normotensive people. It is 
thus important to test the hypotensive effects in hypertensive rats. In the normotensive 
rats 1000 mg/kg was considered the best concentration tested. This concentration was 
thus also tested in our hypertensive rats. A dose of 1000 mg/kg reduced the systolic blood 
pressure significantly from 204.83 ± 4.13 mmHg to 124 ± 6.3 mmHg (p <0.001) and the 
diastolic pressure from 145.00 ± 2.58 mmHg to 90.00 ± 3.62 mmHg (p <0.001). This 
dose thus effectively decreased the blood pressure back to normotensive level. The blood 
pressure was reduced significantly from 13 to 50 mins, which means that the dose of 
1000 mg/kg can produce quick and lasting antihypertensive effect in hypertensive rats. 
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In comparison to the effect on normotensive rats, the dose of 1000 mg/kg has a more 
pronounced effect on hypertensive rats. Systolic blood pressure of hypertensive rats was 
reduced 76.25 ± 4.40 mmHg, which is 80% more (p<0.001) than in normotensive rats 
(42.33 ± 2.77 mmHg). It has previously been shown that ACE inhibitors can cause a 
more pronounced blood pressure lowering effect in hypertensive patients than in 
normotensive people (Urata H, et al, 1990; Giulio SD, et al, 1996; Weber MA, 1997). 
This view is supported in our rat model.  
 
5.5 Effect of chronic treatment 
In our acute treatment experiments 1000 mg/kg was found to be an effective dose to treat 
hypertension in our animals. As shown in Figure 4-4-1 and 4-4-2 this dose effectively 
decreased the blood pressure of the hypertensive rats back to normal values. We thus also 
wanted to determine whether this dose if administered on a daily basis can be used to (i) 
treat our hypertensive animals (ii) prevent our DSS rats from becoming hypertensive. We 
housed two animals per cage (this was done for practical reasons since we had a large 
number of animals at the time). Twice weekly the body weights and the average daily 
water intake for the animals in the cage was determined. The values were used to 
determine the amount of extract that had to be added to the drinking water to administer 
the extract at 1000mg/kg. It can be argued that the approach followed is not accurate or 
proper however, as will be seen in the sections to follow, the approach was effective. 
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5.5.1 Treatment of hypertensive animals 
After one week on the high salt regime our rats became hypertensive with the systolic 
pressure reaching 164.75 ± 2.31 mmHg and diastolic pressure 120.38 ± 1.67 mmHg. 
After one week O africana (1000 mg/kg/day) decreased the systolic pressure to 133.25 ± 
1.94 mmHg and the diastolic pressure to 93.75 ± 1.83 mmHg. The level is not significant 
from the normotensive pressure (before any treatment: 133.25 ± 1.94 systolic and 93.73 ± 
1.83 mmHg diastolic). This indicates that in O africana at 1000 mg/kg/day was effective 
in reducing blood pressure of hypertensive rats back to normal values.  
 
5.5.2 Preventative effects of O africana  
As knowledge increases and the public becomes more health conscious more people 
recognizes the value of preventative treatment either by a modification of lifestyle or by 
the use of supplements. Many people, especially those that are not very disciplined, find 
the latter option more attractive. 
 
After 2 weeks of salt loading the systolic pressure of the DSS rats reached 204.83 ± 4.14 
mmHg and diastolic pressure reached 145.00 ± 2.58 mmHg in the high salt group 
(p<0.001 compared to value prior to salt treatment). The corresponding values in the 
extract treated group were 128.88 ± 2.36 mmHg and 85.63 ± 2.49 mmHg respectively 
(p>0.05 compared to values prior to salt treatment). Unlike the rats in the high salt group 
rats in the extract treated group were active and healthy in appearance.  
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In previous experiments the ACE inhibitor, captopril at a dose of 50 mg/kg (Stephen JL, 
et al, 2006) and the calcium channel blocker, nifedipine at 10 mg/kg (Hisakazu I, et al, 
1980) were found to be effective in preventing hypertension in rats. We thus compared 
the antihypertensive effects of our aqueous O africana extract with the referred doses of 
captopril and nifedipine. In our experiments 1000 mg/kg/day O africana extract was at 
least equally effective as captopril (50 mg/kg) and nifedipine (10 mg/kg). In our 
experiments captopril and nifedipine was administered using gelatine and jelly as vehicle. 
Results have shown that the vehicle did not affect the blood pressure readings in the 
animals (Unpublished article). 
 
5.6 Mechanism of the antihypertensive effects of O africana  
It was previously suggested that ethanolic extracts of O africana may exert its 
antihypertensive effects via modulation of the sympathetic nervous system or by acting as 
an ACE inhibitor (Somova LI, et al, 2003). Chemical analysis of Olea extracts prepared 
from roots and stems suggests that also the aqueous extract of Olea species may have 
ACE inhibitor properties (Osim EE, et al, 1999). One of our objectives was thus to 
determine whether our O africana aqueous extract exert its antihypertensive effects by 
modulating the activity of the RAS. 
 
To achieve this objective we compared the plasma AII levels in our extract treated rats 
with that of captopril (ACE inhibitor) treated rats and nifedipine (calcium channel 
blocker) treated rats. 
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DSS rats receiving tap water (and normal salt) had plasma AII levels of 62.31 ± 1.18 
pg/ml (Figure 4-6). After oral 2% salt loading for 2 weeks plasma AII levels increased to 
270.83 ± 9.76 pg/ml. Administration of the ACE inhibitor, captopril or the O africana 
extract not only prevented the increase in plasma AII levels, but in both cases 
significantly reduced  the levels to 32.06 ± 2.97 pg/ml and 13.57 ± 0.62 pg/ml 
respectively (Figure 4-6). The non – ACE-inhibitor antihypertensive, nifedipine, did not 
prevent the decrease in plasma AII levels (Figure 4-6). We thus conclude that the 
aqueous O africana extract exerts its hypotensive effects at least in part by modulating 
the RAS system. A study (see appendix) by the author of this thesis suggests that the 
extract has ACE inhibitor properties. Our study does not allow us to make such a firm 
conclusion. We were unable to source an angiotensin I assay. Angiotensin I levels, 
together with the angiotensin II levels would allow us to make a firm statement regarding 
the ACE inhibitor activity of the extract. 
 
The O africana extract decreased the heart rate of our rats (Figure 4-5-3) significantly 
compared to control. Previous experiments indicate that captopril may also decrease HR 
(Konstam MA, et al, 2000). These results are confirmed in this study. We can thus not 
exclude the possibility that the extract exerts its hypotensive effects also in part by 
modulating the sympathetic nervous system. One can however argue that also captopril 
appears to have an apparent heart rate lowering effect. However, although there were 
fluctuations in HR, all values were within in normal range. 
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5.7 Conclusions and recommendations 
This study indicates that: 
• An aqueous extract prepared from leaves of O africana has hypotensive 
effects in rats 
• A dose of 1000 mg/kg/day can be used to effectively treat or prevent 
hypertension induced by high salt loading in rats. It is possible that lower 
doses may be equally effective. 
• If the extract is administered by injection the dose which decreased the blood 
pressure most effectively was found to be 1000 mg/kg 
• The extract exerts its hypotensive effects at least in part by modulating the 
RAS, probably by acting as an ACE inhibitor. 
 
Traditionally O africana is not only used to treat hypertension. It is also used to treat 
ailments such as colic and urinary tract infections (Watt JM, 1962; Hutchings A, 1996; 
Iwu MM, 1993). In this study, using bolus injection experiments, we show that the O 
africana extract may decrease the blood pressure of normotensive rats. Normotensive 
persons using O africana injections for ailments such as colic must be made aware of its 
potential hypotensive effects. We recognize such effects will be dose dependent. 
 
We did not use a tea or infusion prepared from the O africana leaves. We do, however, 
believe this study currently most closely represents the form in which the plant is used 
traditionally.  
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5.8 Future studies 
Future studies should investigate the effects of the extract on rats with complications of 
hypertension, such as LVH and heart failure. One also has to determine whether the 
extract can protect the myocardium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75
REFERENCES 
 
Abbott, WS. A method of computing the effectiveness of an insecticide.  Econ. 1925;18:  
265-267. 
 
Agodoa LY, Appel L, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive 
nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285(21):2719-2728. 
 
Ahmad M, Aria J, et al. Noscapine suppresses angiotensin converting enzyme inhibitors-induced 
cough. Nephr. 2005;10: 348–350. 
 
Al-Nozha MM, Ali MS, et al. Arterial hypertension in Saudi Arabia. Anna of Saudi med. 1997; 
17(2): 170-174. 
 
Al-Qarawi SA., Al-Damegh MA, et al. Effect of freeze-dried extract of O europaea on the 
pituitary-thyroid axis in rats. Phytotherapy Research. 2002; 16(3): 286-287. 
 
Alluri AK, Tayi VNR, et al. Assesment of bioactivity of Indian medicinal plants by using brine 
shrimp (Artemia salina) lethality assay. Applied Science and Engineering. 2005;125-134. 
 
Andrew CD, Anna KJ, et al. Screening of Zulu medicinal plants for angiotensin-converting 
enzyme (ACE) inhibitors. Ethnopharm. 1999; 68: 63-70. 
 
Anesini, C. and Perez, C. Screening of plants used in Argentinian folk medicine for antimicrobial 
activity. Ethnopharm. 1993;39(2): 119-128.  
 
Annet MA, Vitullo L, et al. Pregnancy Prevents Hypertensive Remodeling and Decreases 
Myogenic Reactivity in Posterior Cerebral Arteries from Dahl Salt-sensitive Rats: A Role in 
Eclampsia? Physiol Heart Circ Physiol. 2006;doi:10.1152/ajpheart.00980. 
 
Aram VC, George LB, et al for American Heart Association, Inc. The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure. Hyper. 2003;42:1206-1252. 
 
Baha M and Sibai MD. Diagnosis and Management of Gestational Hypertension and 
Preeclampsia. Obstetrics and Gynecol. 2003;102:181-192. 
 
Banaszewski M, Rydlewska-Sadowska W, et al. Captopril or nifedipine? Comparison of rest and 
exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe 
aortic regurgitation.  Heart Valve Dis. 1998;7(5):488-499. 
 
Barone JJ and Roberts HR.. Caffeine consumption. Food Chem Toxicol. 1996;34:119–129. 
 
Barron LA, Giardina JB, et al. High-salt diet enhances vascular reactivity in pregnant rats with 
normal and reduced uterine perfusion pressure. Hyper. 2001;38:730–735. 
 
Barry D and Stephen H. Reducing the population burden of cardiovascular disease by reducing 
sodium intake. Arch Intern Med. 2007;167:1460-1468. 
 
 
 
 
 76
Bethesda, MD. Clinical guidelines on the identification, evaluation and treatment of overweight 
and obesity in adults: the evidence report.  NIH publish.1998:4083. 
 
Black HR and Yi JY. A new classification for hypertension based on relative and absolute risk 
with implications for treatment and reimbursement hypertension. Hyper. 1996;28:719-724. 
 
Breitenbach VF. National list of indigenous trees. Dendrol foundation. Pretoria. 1986. 
 
Brenner BM, Cooper ME, et al. Effects of losartan on renal and cardiovascular outcomes in 
patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. 
 
Brown, DM, Provoost AP, et al. Renal disease susceptibility and hypertension are under 
independent genetic control in the Fawn-Hooded rat. Nature Genet. 1996;12: 44-51. 
 
Bruneton, J. Pharmacognosy, Phytochemistry, Medicinal Plants. Intercept, Hampshire 1995; 
227-353. 
 
Burt VL, Whelton P, et al. Prevalence of hypertension in the US adult population. Results from 
the Third National Health and Nutrition Examination Survey, 1988–1991. Hyper. 1995; 25: 
305–313. 
 
Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hyper 
1994;23: 531–550. 
 
Capretti G. and Bonaconza E. Effects of infusions or decoctions of olive leaves (O europaea) on 
some physical constants of blood and components of metabolism. Giorn.Clin.Med. 1949;30: 
630-642. 
 
Chen PY and Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in 
Dahl/Rapp rats. Hyper. 1993;22:812-818. 
 
Cicosta C, Occhiuto F, et al. Cardiovascular activity of the young shoots and leaves of O 
europaea L. and of oleuropein. Plant Med. Phytother. 1990;24: 264-277. 
 
Collins R, Peto R, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term 
reductions in blood pressure: overview of randomised drug trials in their epidemiological 
context. Lancet. 1990;335:827-838.  
 
Cowley AW, Roman RJ, et al.  Brown Norway chromosome 13 confers protection from high 
salt to consomic Dahl S rat. Hyper. 2001;37:456-461. 
 
Cunningham AB.  African medicinal plants: setting priorities at the interface between 
conservation and primary health care. People and Plants working paper 1. 1993;3-5. 
 
Cushman WC, Reda DJ, et al. Regional and racial differences in response to antihypertensive 
medication use in a randomized controlled trial of men with hypertension in the United States. 
Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch 
Intern Med. 2000;160(6):825-31. 
 
Cutler JA, Follmann D, et al. Randomized trials of sodium reduction: an overview. Clin Nutr. 
1997;65:643-651.  
 
 
 
 
 77
 
Dahl LK. Effects of chronic excess salt feeding. Induction of self sustaining hypertension in rats. J 
Exp Med. 1961;114:231. 
 
Dahl LK, Heine M, et al. Role of genetic factors in susceptibility to experimental hypertension 
due to chronic excess salt ingestion. Nature. 1962;194:480-482. 
 
Dahl LK, Heine M, et al. Effects of chronic excess salt ingestion. Evidence that genetic factors 
play an important role in sustaining hypertension in rats. J Exp Med. 1963;115:1173-1190. 
 
Dahlof B, Devereux RB, et al for LIFE Study Group. Cardiovascular morbidity and mortality in 
the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised 
trial against atenolol. Lancet. 2002;359(9311):995-1003. 
 
De Pasquale R, Monforte MT, et al. Effects of leaves and shoots of O europaea and oleuropein 
on experimental hypercholesterolaemia in the rat. Plant Med. Phytother. 1991;25:134-140. 
 
Devereux RB, Palmieri V, et al. Effects of once-daily angiotensin-converting enzyme inhibition 
and calcium channel blockade-based antihypertensive treatment regimens on left ventricular 
hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study 
evaluating regression of ventricular enlargement (preserve) trial. Circulation. 
2001;104(11):1248-1254. 
 
DiBona GF and Sawin LL. Effect of arterial baroreceptor denervation on sodium balance. 
Hyper. 2002;40:547–551. 
 
Ebrahim S and Smith GD. Lowering blood pressure: a systematic review of sustained effects of 
non-pharmacological interventions. Public Health Med. 1998;20(4):441-448. 
 
Eckel RH and Krauss RM for the American Heart Association Nutrition Committee. American 
Heart Association call to action: obesity as a major risk factor for coronary heart disease. 
Circulation. 1998;97:2099–2100. 
 
Eichhorn EJ. Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. 
Cardiol Clin. 1998;16:711-725. 
 
El-Ghazaly MA, Abdallah DM, et al. Blood pressure lowering effect of an olive leaf extract (O 
europaea) in induced hypertension in rats. Arzneimittel-Forschung. 2002;52(11): 797-802. 
 
Emter CA, McCune SA, et al. Low-intensity exercise training delays onset of decompensated 
heart failure in spontaneously hypertensive heart failure rats. Physiol. Heart Circ. Physiol. 2005; 
289(5):H2030-2038.  
 
Eskander EF and Jun HW. Hypoglycaemic and hyperinsulinaemic effects of some Egyptian herbs 
used for the treatment of Diabetes mellitus (Type II) in rats. Pharm Sciences. 1995;36(1-6): 
331-342. 
 
Et-taouil K, Schiavi P. Sodium intake, large artery stiffness, and proteoglycans in the 
spontaneously hypertensive rat. Hyper. 2001;38:1172–1176. 
 
 
 
 
 
 78
Fabricant DS and Farnsworth NR. The value of plant used in traditional medicine for drug 
discovery. EHPS. 2001;109 (S1). 
 
Fehri B, Aiache JM, et al. O europaea L: stimulant, anti-ulcer and anti-inflammatory effects. 
Boll. Chim. Pharm. 1996; 135(1): 42-49. 
 
Fox SI. Human Physiol. McGraw Hill. Boston. 2002. 
 
Franklin SS, Gustin W, et al. Hemodynamic patterns of age-related changes in blood pressure. 
The Framingham Heart Study. Circulation. 1997; 96: 308–315. 
 
Frost CD, Law MR, et al. By how much does dietary salt reduction lower blood pressure? II. 
Analysis of observational data within populations. BMJ. 1991;302:815–818. 
 
Fuchs FD, Chambless LE, et al. Alcohol consumption and the incidence of hypertension: the 
Atherosclerosis Risk in Communities Study. Hyper. 2001;37:1242–1250. 
 
Ganten D and Mulrow PJ. Pharmacology of Antihypertensive Therapeutics. Springer-Verlag 
Berlin Heiderberg. London. 1990. 
 
Garrett MR, Joe B, et al. Identification of blood pressure quantitative trait loci that differentiate 
two hypertensive strains. Hyper. 2002;20:2399-2406.  
 
Garry PR and John HB. Pharmacologic treatment of hypertension.2001;25. 
 
Gilderman L, Weinberger M, et al. Efficacy of ACE inhibitor/CCB vs. ACE inhibitor/diuretic 
fixed combination therapy for the treatment of essential hypertension. Hyper. 2005;18:A87-A87. 
 
Giulio SD, Cherubini C, et al. ACE-inhibitors in renal hypertension. Hyper. 1996 : One 
Medicine, Two Cultures. 
 
Gonzalez M, Zarzuelo A, et al. Hypoglycaemic activity of olive leaf. Planta Medica. 1992; 58(6): 
513-515. 
 
Grange JM and Davey RW. Detection of antituberculous activity in plant extracts. Applied 
Bacteriology. 1990; 68(6): 587-591. 
 
Griffith LE, Guyatt GH, et al. The influence of dietary and nondietary calcium supplementation 
on blood pressure: an updated metaanalysis of randomized controlled trials. Hyper.1999; 
12:84-92. 
 
Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 
2002;105:2696–2698. 
 
Guerin JC and Reveillere HP. A study of 40 plant extracts against 9 fungal species. Anna 
Pharmac Françaises. 1985; 43(1): 77-81. 
 
Hagberg JM, Park JJ, et al. The role of exercise training in the treatment of hypertension: an 
update. Sports Med. 2000; 30(3):193-206. 
 
 
 
 
 
 79
Han YM, Nishibe S, et al. Inductive effects of olive leaf and its component oleuropein on mouse 
liver glutathione S-transferases. Natural Med. 2002; 55(2): 83-86. 
 
Hansen K, Nyman U, et al. In vitro screening of traditional medicines for anti-hypertensive 
effect based on inhibition of the angiotensin converting enzyme (ACE). Ethnopharm. 
1995;48: 43-51. 
 
Hansson L, Zanchetti A, et al for HOT Study Group. Effects of intensive blood-pressure lowering 
and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal 
Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755-1762. 
 
Hartley TR, Sung BH, et al. Hypertension risk status and effect of caffeine on blood pressure. 
Hyper. 2000;36:137–141. 
 
He J and Whelton PK.  What is the role of dietary sodium and potassium in hypertension and 
target organ injury? Med Sci. 1999;317(3):152-159. 
 
Heyen JRR, Blasi ER, et al. Structural, functional, and molecular characterization of the SHHF 
model of heart failure. Physiol. 2002;283: H1775-H1784. 
 
Hisakazu I, Keizo I, et al. Different antihypertensive effects of nifedipine in conscious 
experimental hypertensive and normotensive rats. Pharmacol. 1980; 64:21-29. 
 
Hutchings A. Zulu medicinal plants. Natal University Press. 1996. 
 
Inoko M, Kihara Y, et al. Transition from compensatory hypertrophy to dilated, failing left 
ventricles in Dahl salt-sensitive rats. Physiol. 1994;26:2471-2482. 
 
Iwu MM. Handbook of African medicinal plants. CRC Press. 1993. 
 
Jafar TH, Schmid CH, et al. Angiotensin-converting enzyme inhibitors and progression of 
nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001; 
135(2):73-87. 
 
Jee SH, He J, et al. The effect of chronic coffee drinking on blood pressure: a meta-analysis of 
controlled clinical trials. Hyper. 1999;33(2):647-652. 
 
Johnston CI, Burrell LM, , et al. The Tissue Renin-angiotensin-system and its functional role. 
Clin and Expe Pharmacol and Physiol. 1992;19:1440-1681. 
 
Kannel WB, Brand M, et al. The relation of adiposity to blood pressure and development of 
hypertension. The Framingham study. Ann Intern Med 1967;67:48-59. 
 
Kawano Y, Matsuoka H, , et al. Effects of magnesium supplementation in hypertensive patients: 
assessment by office, home, and ambulatory blood pressures. Hyper. 1998;32(2):260-265.  
 
Khayyyal MT, El-Ghazaly MA, et al. Blood pressure lowering effect of an olive leaf extract 
(Olea europaea) in induced hypertension in rats. Arzneimittel-Forschung. 2002;52(11): 797-802. 
 
Klatsky AL, Friedman GD, et al. Alcohol consumption and blood pressure Kaiser-Permanente 
Multiphasic Health Examination data. N Engl J Med 1977;296:1194 –1200. 
 
 
 
 
 80
 
Konstam MA, PattenRD, et al. Effects of losartan and captopril on left ventricular volumes in 
elderly patients with heart failure: Results of the ELITE ventricular function substudy. Am J 
Heart. 2000;139(6):1081-1087. 
 
Law MR, Frost CD, et al. By how much does dietary salt reduction lower blood pressure? I. 
Analysis of observational data among populations. BMJ 1991;302:811–815. 
 
Leiter LA, Abbott D, et al. Lifestyle modifications to prevent and control hypertension. 2. 
Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian 
Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease 
Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ. 
1999;160:S7-12.703-13.  
 
Li P, Mariana M, et al. Cardiovascular, endocrine, and body fluid-electrolyte responses to salt 
loading in mRen-2 transgenic rats. Physiol Heart Circ Physiol 1998;275:1130-1137. 
 
Li XN, Benjamin IS, et al. A new rat model of portal hypertension induced by intraportal 
injection of microspheres.WJG. 1998;4(1):66-69. 
 
MacGregor GA. Sodium and potassium intake and blood pressure. Hyper. 1983;5:III79-84. 
 
MacMahon S. Alcohol consumption and hypertension. Hyper, 1987; 9: 111-121. 
 
Maheswaran R, Gill JS, et al. High blood pressure due to alcohol. A rapidly reversible effect. 
Hyper. 1991;17:787-792. 
 
Maiorano G, Bartolomucci F, Contursi V, et al. Effect of alcohol consumption versus abstinence 
on 24-h blood pressure profile in normotensive alcoholic patients. Hyper. 1995;8:80–81. 
 
Manceau P, Netien G, et al. Hypoglycaemic action of extracts of olive leaves. Comptes rendues 
de la Sociéte Biologique. 1942;136:810-811. 
 
Matthew RW, James MG, et al for the Trandolapril Multicenter Study Group. Differing 
Mechanisms of Action of Angiotensin-Converting Enzyme Inhibition in Black and White 
Hypertensive Patients. Hyper. 1995; 26:124-130. 
 
Meyer BN, Ferrigni NR, et al. Brine shrimp: a convenient general bioassay for active plant 
constituents. Med plant research. 1982; 45: 31-34. 
 
Meyer JJM, Afolayan AJ, et al. Inhibition of herpes simplex virus type 1 by aqueous extracts 
from shoots of Helichrysum qureonites (Asteraceae). Ethnopharm. 1996; 52:41–43. 
 
Mozaffari MS, Patel C, , et al. NaCl-induced hypertensive rat model of non-insulin-dependent 
diabetes: role of sympathetic modulation. Hyper.2000; 13: 540-546. 
 
Müller DN and Luft FC. The renin-angiotensin system in the vessel wall. Basic Research in 
Cardiol. 1998;93:7-14. 
 
Muhizi T. The extraction, purification and evaluation of compounds from the leaves of Leonotis 
leonorus for anticonvulsant activity. A Master’s thesis. University of the Western Cape. 2002. 
 
 
 
 
 81
 
Myron HW, Naomi SF, , et al. Salt Sensitivity, Pulse Pressure, and Death in Normal and 
Hypertensive Humans. Hyper. 2001;37:429-432. 
 
Nagaoka A, Iwatsuka H, , et al. Genetic predisposition to stroke in spontaneously hypertensive 
rats. Physiol. 1976;230: 1354-1359.  
 
Nasser M, Michael S, et al. Obesity and Hypertension Progress. CAD. 1999;42:39-58. 
 
Neal B, MacMahon S, et al. Blood Pressure Lowering Treatment Trialists' Collaboration.Effects 
of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of 
prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment 
Trialists' Collaboration. Lancet. 2000;356:1955-1964. 
 
Ojewole JAO, Kamadyaapa DR, et al. Some in vitro and in vivo cardiovascular effects of Hypoxis 
hemerocallidea Fisch & CA Mey (Hypoxidaceae) corm (African potato) aqueous extract in 
experimental animal models. Cardio J of SA. 2006;17:166-171.  
 
Osim EE, Mbajiorgu EF, et al. Hypotensive effect of crude extract Olea. africana (Oleaceae) in 
normo and hypertensive rats. Cent Afr J Med.1999;45(10):269-274. 
 
Paul RC, Dominic C, et al. The Effect of Dietary Patterns on Blood Pressure Control in 
Hypertensive Patients: Results From the Dietary Approaches to Stop Hypertension (DASH) Trial. 
Hyper. 2000;13:949–955. 
 
Peng HM, Oscar A, et al. Angiotensin-Converting Enzyme Inhibitors. A New Mechanism of 
Action. Circul. 2005;112:2436–2445. 
 
Perez C and Anesini C. In vitro antibacterial activity of Argentine folk medicinal plants against 
Salmonella typhi. Ethnopharm. 1995; 44(1): 41-46. 
 
Petkov V and Manolov P. Pharmacological analysis of the iridoid oleuropein. 
Arzneimittelforschung. 1972;22(9):1476-1486. 
 
Pieroni A, Heimler D, et al. In vitro anti-complementary activity of flavonoids from olive (O 
europaea L.)leaves. Pharmazie. 1996;51(10): 765-768. 
 
Pincomb GA, Lovallo WR, et al. Effects of caffeine on vascular resistance, cardiac output and 
myocardial contractility in young men. Cardiol. 1985;56:119–122. 
 
Pincomb GA, Wilson MF, , et al. Effects of caffeine on pressor regulation during rest and 
exercise in men at risk for hypertension.  Am Heart J 1991;122:1107–1115. 
 
Piotr J and Jolanta Z. Heart rate changes in partially restrained rats during behaviorally and 
pharmacologically evoked emotional states. Acta Neurobiol. Exp. 2001; 61: 53-67. 
 
Psaty BM, Smith NL, et al. Health outcomes associated with antihypertensive therapies used as 
first-line agents. A systematic review and meta-analysis. JAMA. 1997;277(9):739-745.  
 
 
 
 
 
 82
Puri VN and Saha S. Comparison of acute cardiovascular effects of cadmium and captopril in 
relation to oxidant and angiotensin converting enzyme activity in rats. Drug and chem toxi. 
2003;26:213-218. 
 
Radevski IV, Valtchanova ZP, et al. Antihypertensive effect of low-dose hydrochlorothiazide 
alone or in combination with quinapril in black patients with mild to moderate hypertension. Clin 
Pharm. 2000;40(7):713-721. 
 
Rainnie DG, Grunze HC, et al. Adenosine inhibition of mesopontine cholinergic neurons: 
implications for EEG arousal. Science 1994;263:689–692. 
 
Ramachandran SV, Alexa B, et al. Residual Lifetime Risk for Developing Hypertension in 
Middle-aged Women and Men: The Framingham Heart Study. AMA. 2002; 287: 1003-1010. 
 
Rapp JP and Dene H. Development and characteristics of inbred strains of Dahl salt-sensitive 
and salt-resistant rats. Hyper. 1985; 7: 340-349. 
 
Rauwald HW, Brehm O, et al. Screening of 9 vasoactive medicinal plants for their possible 
calcium antagonistic activity. Strategy for the selection and isolation of the active principles of O 
europaea and Peucedanum ostruthium. Phytothe Research. 1994;8: 135-140. 
 
Ribeiro RA, Barros F, et al. Acute diuretic effects in conscious rats produced by some medicinal 
plants used in the state of Sao Paulo, Brazil. Ethnopharm. 1988;24(1): 19-29. 
 
Robertson D, Frolich JC, et al. Effects of caffeine on plasma renin activity, catecholamines and 
blood pressure. N Engl J Med 1978;298:181–186. 
 
Sacks FM, Svetkey LP, et al for DASH-Sodium Collaborative Research Group. Effects on blood 
pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) 
diet. DASH. N Engl J Med. 2001;344(1):3-10. 
 
Schmieder RE, Schlaich MP, et al. Update on reversal of left ventricular hypertrophy in essential 
hypertension (a meta-analysis of all randomized double-blind studies until December 1996). 
Nephrol Dial Transpl. 1998;13(3):564-569.  
 
Sepehrdad R, Chander PN, et al. Sodium transport antagonism reduces thrombotic 
microangiopathy in stroke-prone spontaneously hypertensive rats. Physiol. 
2004;286(6):F1185-1192. 
 
Somova LI and Channa ML. Glucose metabolism and insulin sensitivity in Dahl hypertensive 
rats. Methods Find Exp Clin Pharmacol. 1999;21(6):421-426. 
 
Somova LI, Nadar A, et al. Cardiovascular, antihyperlipidemic and antioxidant effects of 
oleanolic and ursolic acids in experimental hypertension. Phytomed. 2003;10: 115–121.  
 
Somova LI, Shode FO, et al. Antihypertensive, antiatherosclerotic and antioxidant activity of 
triterpenoids isolated from O europaea, subspecies africana leaves. Ethnopharm. 2003; 
84:299-305. 
 
Somova LI, Shode FO, et al. Cardiotonic and antidysrhythmic effects of oleanolic and ursolic 
acids, methyl maslinate and uvaol. Phytomed. 2004; 11:121-129. 
 
 
 
 
 83
South Africa Demographic and Health Survey. 1998: 263-277. 
 
Stamler J. The Intersalt Study: background, methods, findings. Clin Nutr. 1997; 65: 626–642. 
 
Stephen JL, Maleka PH, et al. ACE inhibition restores the vasodilator potency of the 
endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously 
Hypertensive rats. Vascular Pharm. 2006; 44:491–507. 
 
Stephen R and Joseph S. Pathogenicity and virulence. Invert Pathol. 2004;85:146–151. 
 
Steyn K, Bradshaw D, et al. Hypertension in South Africa. The South African Demographic and 
Health Survey. Poverty and inequity: The challenges for Public Health in Southern Africa. 2000. 
 
Steyn K, Gaziano TA, et al. Hypertension in South African adults: results from the Demographic 
and Health Survey, 1998. Hyper. 2001; 19: 1717–1725. 
 
Stevens VJ, Obarzanek E, et al. Trials for the Hypertension Prevention Research Group. 
Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension 
Prevention, phase II.. Ann Intern Med. 2001;134(1):1-11. 
 
Sung BH, Lovallo WR, et al. Effects of caffeine on blood pressure response during exercise in 
normotensive healthy young men. Cardiol 1990;65:909–913. 
 
Terry RH, William RL, et al. Cardiovascular Effects of Caffeine in Men and Women. Am J 
Cardiol 2004;93:1022–1026. 
 
Thomas AP, Steven NB, et al for the American Heart Association, Inc. Guidelines for Primary 
Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation. 2002;106:388. 
 
Trovato A, Forestieri AM, et al. Hypoglycaemic activity of different extracts of O europaea L. in 
the rat. Plant Med Phyother. 1993;26(4): 300-308. 
 
Urata H, Healy B, et al. Angiotensin II-forming pathways in normal and failing human hearts. 
Circulation. 1990;66:883-890. 
 
Vasan RS, Beiser A, et al. Residual lifetime risk for developing hypertension in middle-aged 
women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003-1010. 
 
Walter HL, Memory PF, et al. Medical botany: plants affecting human health. 2003.180-219. 
 
Watt JM and Breyer MG. The medicinal and poisonous plants of Southern and Eastern Africa. 
2nd edition. 1962. 
 
Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting 
enzyme inhibitors in the treatment of hypertension. Hypertens Suppl. 1997;15(6):S31-36. 
 
Whelton PK, Appel LJ, et al. Sodium reduction and weight loss in the treatment of hypertension 
in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly 
(TONE). TONE Collaborative Research Group. JAMA. 1998;279(11):839-46. 
 
 
 
 
 
 84
World Health Organization/International Society of Hypertension (WHO/ISH). Guidelines for the 
Management of Hypertension. Hyper. 1999; 17:151-183. 
 
World Health Organization (WHO). Cardiovascular Diseases– Prevention and Control. 2002-a. 
 
World Health Organization (WHO). The World Health Report 2002: Reducing risks, promoting 
healthy life. Geneva. 2002-b. 
 
World Health Organization/ International Society of the Hypertension Writing Group 
(WHO/ISH). 2003 World Health Organization (WHO)/International Society of Hypetension 
(ISH) statement on management of hypertension. Hyper. 2003; 21:1983-1992. 
 
Xin X, He J, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized 
controlled trials. Hyper. 2001;38(5):1112-1117. 
 
Yasuki K and Shigetake S. Transition from compensatory hypertrophy to dilated failing left 
ventricle in Dahl salt-sensitive rats.  Hyper. 1997;105-124. 
 
Zarzuelo A, Duarte J, et al. Vasodilator effect of olive leaf. Planta Medica. 1991; 57(5): 417-419. 
 
Zhu M. The Medical Classic of the Yellow Emperor. 2001. 
 
http://davesgarden.com/guides/terms/go/573/ 
 
http://www.health24.com/medical/Condition_centres/777-792-815-1778,16793.asp 
 
http://www.healthy.net/scr/Article.asp?Id=1283&xcntr=1. 
 
http://www.med.yale.edu/yarc/vcs/normativ.htm 
 
http://www.nps.gov/plants/medicinal/ 
 
http://www.williams.edu/biology/Faculty_Staff/sswoap/site/ratmousepic.htm 
 
 
 
 
 
 
 
 
 
 
 
 
 85
Appendix   
 
The antihypertensive effects of Olea africana phytotherapy 
 
X. Wang, J. Adams, Q. Johnson and S. Thamburan 
 
 
 
ABSTRACT 
 
Hypertension is becoming an increasingly common global health problem, despite the use 
of many synthetic drugs for this condition. Olea africana is one of the many 
phytotherapies that has been used indigenously to modulate hypertension for years. In the 
current study, the inhibitory activity of ethanol extracts of Olea africana (OAE), pure 
oleanolic acid (OA), aqueous extracts of Olea africana (OAW) and the synthetic drug 
Captopril (Cap) on angiotension converting enzyme (ACE) levels in whole blood in 
normotensive and hypertensive rats were compared in vitro. The results indicate that OA 
produced mild inhibitory activity of ACE levels, while Captopril, OAE and OAW 
produced more significant inhibition effect. The Cmax of Captopril was 0.04mg/ml, which 
reduced ACE levels to 976.87±25.38pg/ml (control level in normotensive rats was 
1172.24±28.62 pg/ml) and 1397.52±87.95 pg/ml (control level in hypertensive rats was 
1810.36±32.11 pg/ml). The peak inhibition effect in normotensive and hypertensive rats 
was observed in OAW at dose of 1.00mg/ml, which reduced ACE levels 28.94±5.27% 
and 34.01±9.89%.  In conclusion, aqueous and ethanol extracts of Olea africana 
produced greater lowering of ACE levels compared to Captopril and OA.  OAW 
showed most significant ACE inhibitory effect among all the four tested reagents. Hence, 
further research on the anti-hypertensive effects of Olea africana extracts is 
recommended. 
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Key words: Hypertension, ethanol extracts of Olea africana, aqueous extracts of Olea 
africana, Captopril, oleanolic acid, angiotension converting enzyme, phytotherapy. 
 
INTRODUCTION 
 
Hypertension is becoming an increasingly common health problem worldwide because of 
increasing longevity and prevalence of contributing factors such as obesity, physical 
inactivity and an unhealthy diet.1 Worldwide, hypertension is estimated to cause 7.1 
million premature deaths and 4.5% of the disease burden annually.2  
 
The main treatment of hypertension still relies on synthetic medicines. 3 Three main drug 
classes have been used in the treatment of hypertension in the past forty years. 4, They are 
diuretics, Beta blockers (β-blockers) and calcium channel blockers (CCBs). 5,6 The data 
from more than 20 randomized controlled trials conclusively demonstrate reductions in 
both mortality and morbidity with these three drug classes. 3 Now, a newer class, 
angiotensin converting enzyme inhibitors (ACEI’s), is being widely used against the 
older classes. 5 
 
The use of these synthetic medicines however, has some negative effects. Most drugs 
used to treat hypertension have been evaluated for a number of specific populations; 
these include ACEI’s, B-blockers, CCB’s and diuretics in patients with concomitant 
diabetes, nephropathy, coronary and cerebrovascular disease, heart failure, and left 
ventricular hypertrophy.3 Other side effects of these synthetic medicines have also been 
reported; for example, dry cough is a common side-effect of ACEI’s and is a major 
limiting factor of their use.7 Secondly, despite the availability of useful non-drug therapy 
and potent medications, treatment is too often ineffective, mainly as a consequence of the 
patient’s lack of compliance with therapeutic regimens. 3 Moreover, because of limited 
resources, synthetic drug treatment may be not affordable to the majority of hypertensive 
patients. 
 
On the other hand, there are many herbal medicines traditionally used to treat 
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hypertension in countries such as China8, 9, Japan10, South Africa11, Morocco12 and 
Cameroon13. For example, Chinese Peristrophe roxburghiana,8 Hibiscus sabdariffa,9  
Japanese Toki-shakuyaku-san10 and Cameroon’s Mitragyna ciliate13 have been 
traditionally used to treat hypertension in local regions for years. These herbal medicines 
are much easier and cheaper to obtain than the synthetic medicines, 14 and fewer side 
effects are reported. 
 
Oleanolic acid (OA) is a triterpenoid compound, found in more than 120 plant species.15 
OA has been shown to have many pharmacological properties, including antihypertensive 
activity.11 Olea europaea is a medicinal plant that has shown significant antihypertensive 
effects by it’s ACE inhibitory activity.16, 17 Olea africana is a subspecies of Olea 
europaea and is indigenous to Africa. 18   In traditional medicine, this plant is used as a 
diuretic, hypotensive, emollient, febrifuge and tonic, for urinary and bladder infections 
and for headaches. 19 In scientific studies, the extract of the leaves, root and stem of Olea 
africana has been shown to possess antihypertensive activity.20,21   
 
MATERIALS AND METHODS 
 
Plant material 
Leaves of Olea africana were collected on the campus of the University of the Western 
Cape (UWC) in South Africa, between September and October 2004. Fresh leaves were 
washed, air dried and ground into powder.  
 
Ethanol extract was prepared by shaking the ground powder in twice its weight of 
ethanol and allowing it to stand for 12 hours, after which it was vacuum filtered. The 
filtrate was then evaporated to dryness at 40℃, using a rotary evaporator. Before use, the 
extract was weighed and dissolved in a known volume of distilled water and then serially 
diluted to 0.02mg/ml, 0.04mg/ml and 0.08mg/ml. The ethanol extracts were stored at 4 ℃ 
until use.  
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Aqueous extract was obtained by shaking the powder in distilled water and allowing it 
to stand for 24 hours before filtering, using a filter paper. The filtrate was then evaporated 
to 10% of its original volume using a rotary evaporator at a temperature of 40℃. The 
reduced volume of the filtrate was first frozen overnight and then freeze dried for 24 
hours to obtain a fine powder. The powder was weighed and dissolved in a known 
volume of distilled water and then serially diluted to 0.50 mg/ml, 1.00 mg/ml and 2.00 
mg/ml. The aqueous extracts were stored at 4 ℃ until use. 
 
Oleanolic acid 
Pure oleanolic acid (Sigma Aldrich) was stored at 4℃. Before use, OA was brought to 
room temperature and then serially diluted to 0.50 mg/ml, 1.00 mg/ml and 2.00 mg/ml. 
 
Animals 
Dahl salt-sensitive (DSS) genetically hypertensive rats and control normotensive Dahl 
salt-resistant (DSR) rats were ordered from the University of Kwazulu-Natal, South 
Africa. Male rats (6 weeks old), weighing 200–250g at the beginning of the experiment, 
were used. Rats were bred in the Medical Bioscience Department animal house, UWC 
and housed individually in polyethylene cages with water and standard food provided ad 
libitum. Animal room temperature was maintained at 26±2℃, with constant humidity and 
a 12-h light/dark cycle.  
 
The control normotensive DSR rats received normal saline for 3 weeks. The DSS rats 
received high-salt diet (8% NaCl) for 3 weeks to induce hypertension.22 
 
Before use, rats were anesthetized with sodium pentobarbital (40 mg /kg i.p.) and the 
chests were quickly opened. Injectors were used to collect blood (2ml) from the most 
strongly beating position of hearts. 
 
Whole Blood Assay 
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Collected blood was immediately transferred into lithium heparin glass tubes (BD 
Company) and lightly inverted several times. Blood was diluted 1:5 with RPMI 1640 
medium. Cell culture was carried out in sterile 96-well (NUNC) plates under aseptic 
conditions. 180µl of diluted blood was transferred to wells of the 96 well plate. The 
negative control consisted of 20µl of medium added to 180µl of blood. The positive 
control consisted of 20 µl of Captopril (Adcock Ingram Ltd.) added to the blood culture, 
as Captopril is an ACEI and has been proven to inhibit ACE levels.23 The experiment 
consisted of 20µl of either Olea africana ethanol extract (OAE) or pure oleanolic acid 
(OA) added to the diluted blood. The cultured blood was then incubated for 1-1.5 hours 
in a humidified incubator at 37℃ and 5% CO2. The blood was stimulated in the presence 
and absence of Captopril or OAE or OA. After incubation, the supernatants were 
collected and stored at -20℃ for determination of blood ACE levels. 
 
ACE Assay 
The human ACE Quautikine immunoassay kit (R&D Systems, Catalog No.DACE00) 
was used for the analysis of ACE levels. Before use, the reagents, samples and ACE 
standards were brought to room temperature. First 100µl Assay Diluent was added to 
each well. Then 50µl ACE standard, supernatants of the negative control, positive control 
or plant extract was added to different wells. The plate was then incubated for 2 hours on 
a shaker at room temperature.  The wells were then aspirated and washed 4 times before 
200µl ACE conjugate was added to each well. The plate was incubated for 2 hours again 
on the shaker at room temperature. The wells were then aspirated and washed 4 times 
again. 200µl substrate solution was then added to each well and the plate was incubated 
for 30 minutes at room temperature on the benchtop, protected from light. Then 50µl stop 
solution was added to each well. The data was read at 450nm on a microplate reader 
(Labsystems Multiskan® MCC/340).  
 
Statistical analysis 
 
 
 
 
 90
All data are expressed as mean± standard error of the mean (SEM) and analysed by 
analysis of variance (ANOVA) test. The SPSS V12.0 was used, including one-way 
student’s t-test. A p value of 0.05 or less was considered statistically significant. 
 
RESULTS 
Comparison of Captopril, OAE, OA and OAW against Control 
 
Normotensive Rat Experiments 
The control mean ACE level in whole blood in normotensive rats was 1172.24±57.37 
pg/ml.  
Graded doses of Captopril (0.02mg/ml to 0.08mg/ml), OAE, OA and OAW (0.50mg/ml 
to 2.00mg/ml) produced significant drops of ACE levels (p＜0.05 , Figure 1&2).  At 
dose of 0.04mg/ml, Captopril displayed best ACE levels reduction, which decreased ACE 
levels down to 976.87±25.38pg/ml. OAW, OA and OAW showed best ACE inhibitory 
effect at dose of 1.00mg/ml, and the lowest ACE level was observed in OAW, which was 
831.14±45.55pg/ml. 
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Figure 1. ACE levels reduction effect of 
Captopril in normotensive rats 
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Figure 2. ACE levels reduction effect of OAE, 
OA and OAW in normotensive rats 
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Figure 3. ACE levels reduction effect of 
Captopril in hypertensive rats 
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Figure 4. ACE levels reduction effect of OAE, 
OA and OAW in hypertensive rats 
 
Hypertensive Rat experiments 
The control mean ACE level in whole blood in hypertensive rats was 1810.36±70.11 
pg/ml. 
ACE levels drops were observed and expressed in Figure 3&4. All these 4 tested reagents 
at different doses showed significant drops(p＜0.01) . The lowest ACE level was also 
observed in OAW at dose 1.00mg/ml, which was 1193.26±69.76pg/ml. 
 
Comparison of OAE, OAW and Captopril 
When compared to Captopril, at all the doses administrated (0.50, 1.00 and 2.00mg/ml), 
OAE and OAW produced greater decrease in ACE levels than corresponding doses of 
Captopril (0.02, 0.04 and 0.08mg/ml) in both normotensive and hypertensive rats (Figure 
5-8, p＜0.05 to 0.01). For normotensive rat experiments, the decrease percentage of ACE 
levels in OAE and OAW (1.00mg/ml) were observed as 22.85±3.84% and 28.94±5.27% 
against 16.72±3.23% in Captopril (0.04mg/ml). For hypertensive rat experiments, the 
numbers come up to 28.32±7.25% and 34.01±9.89% (OAE and OW at 1.00mg/ml) 
against 22.79±4.14% (Captopril at 0.04mg/ml). 
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Figure 5. Decrease percentage of ACE levels of 
Captopril in normotensive rats 
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Figure 6. Decrease percentage of ACE levels of OAE, OA 
and OAW in normotensive rats 
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Figure 7. Decrease percentage of ACE levels of 
Captopril in hypertensive rats 
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Figure 8. Decrease percentage of ACE levels of OAE, OA 
and OAW hypertensive rats 
 
Comparison of OAE, OAW and OA 
Although OA also produced significant ACE inhibitory effect, Data showed that OA is 
not as powerful as OAE or OAW.  At all doses, OAE and OAW displayed greater 
lowering of ACE levels, especially at dose of 1.00mg/ml in hypertensive rat experiments, 
where OA produced 11.20±4.44% of reduction, while OAE and OAW produced 
28.32±7.25% and 34.01±9.89% (Figure 6&8, p＜0.001). 
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Comparison of OAE and OAW  
 
Even OAE and OAW come from same plant and both produced greater ACE inhibitory 
effects than Captopril and OA, however, their effect are not exactly same. In fact, at all 
the doses administrated, OAW showed greater reduction of ACE levels than 
corresponding  doses of OAE (Figure 6&8, p＜0.05). 
 
DISCUSSION 
 
The results from previous studies have confirmed that two inhibitors of ACE (Captopril 
and OA) produce an antihypertensive response in rats1,6,7, however, ACE levels were 
seldom tested in these studies. This may be the first time to determine the ACE levels 
reduction in whole blood by comparing Captopril, Olea africana extracts, and oleanolic 
acid.  
 
As presented above, all these four reagents administrated showed significant inhibition of 
ACE levels in whole blood. Cmax of Captopril was 0.04mg/ml. Cmax of OAE, OA and 
OAW was 1.00mg/ml. However, both OAE and OAW produced greater reduction of 
ACE levels when compared to Captopril and OA. In addition, OAW seems to be more 
effective than OAE according to the results. 
 
Oleanolic acid is one of the compounds of Olea africana extract, but the results showed 
that OA is not as effective as OAE or OAW. It seems that OA alone might not produce 
significant anti-hypertensive effect as OAE or OAW. The interactions of OA and other 
compounds in Olea africana extract appear to be complex and additional work need to be 
done to more fully understand this biology. 
 
As classic ACE inhibitor for the treatment of hypertension, Captopril produced 
significant ACE inhibition in whole blood. However, OAE and OAW produced greater 
effect than Captopril. Considering the side effect of Captopril which can’t be ignored, 
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Olea africana extract seems to be a better choice to treat hypertension for its less 
negative effect. Furthermore, OAE and OAW are also easier to be prepared. 
 
Olea africana is widespread in Africa. It is easier to obtain and costs less than synthetic 
medicines.18 The cost of antihypertensive treatment, especially in developing countries 
with rich herbal resources and declining economies, might be reduced by resorting to 
scientifically proven herbal treatments such as the Olea africana extracts studied here. 
This study may validate the use of the aqueous and ethanol extracts of Olea africana in 
the treatment of some forms of hypertension. 
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